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ABSTRACT
STRUCTURAL AND FUNCTIONAL STUDY OF MULTIDRUG MEMBRANE
TRANSPORTERS
Feng Ding 
Old Dominion University, 2013 
Director: Dr. Xiao-Hong Nancy Xu
Multidrug membrane transporters (efflux pumps) in both prokaryotes and 
eukaryotes are responsible for ineffective treatment of a wide variety of diseases, 
including infections and cancer, underscoring the importance of better 
understanding of their structures and functions for design of effective therapies. 
Despite extensive studies over decades, their underlying molecular mechanisms 
remain largely unknown. In this dissertation, we focus on the study of structures 
and functions of multidrug membrane transporters, including ATP-binding 
cassette transporter (BmrA) and Resistance-Nodulation-Cell Division transporter 
(MexA,B-OprM) in gram-positive and gram-negative bacteria (Bacillus subtilis 
and Pseudomonas aeruginosa), respectively. We fused EGFP with N-terminus 
and C-terminus of BmrA to construct BmrA-EGFP fusion proteins and 
characterized their efflux functions in four strains of bacterial cells (Ct-BmrA- 
EGFP, Nt-BmrA-EGFP, BmrA and ABmrA, B. subtilis) using fluorescence 
microscopy and spectroscopy. The results show that BmrA-EGFP fusion proteins 
exhibit the similar efflux kinetics of BmrA and retain the efflux functions of BmrA. 
Modeled structures of the fusion proteins show a highly flexible linker region 
connecting EGFP with BmrA, suggesting a minimal obstruction of EGFP to 
BmrA. These two new strains of BmrA-EGFP offer the possibility for one to
visualize and study efflux function and mechanisms of BmrA transporters. We 
further studied the size-dependent efflux functions of BmrA-EGFP and BmrA 
using single plasmonic nanoparticle imaging probes and spectroscopy and found 
size-dependent efflux kinetics of BmrA. Using similar approaches, we fused 
EGFP with MexA,B-OprM transporters and characterized their efflux functions 
using fluorescence spectroscopy and single NP plasmonic spectroscopy. The 
results show that EGFP fused MexA,B-OprM only partially retains its original 
efflux functions. Structural analysis of fusion protein suggests possible steric 
hindrance of EGFP toward the conformation changes of MexA,B-OprM, which 
led to the steric effect upon their efflux functions. These important findings offer 
new insights into the structural and functional studies of multidrug membrane 
transporters (efflux pumps), and demonstrate the powerful new 
nanobiotechnology for better understanding of multidrug resistance.
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The phenomena of multidrug resistance (MDR) have been identified in 
many types of species ranging from bacterium to human, due to existence of 
different types of efflux pumps such as the major facilitator (MF) superfamily, the 
small multidrug resistance (SMR) family, the resistance-nodulation-cell division 
(RND) family and the ATP binding cassette (ABC) superfamily [1-8]. 
Overexpression of some ABC pumps often causes the failure of clinical 
chemotherapies in many types of human diseases such as cystic fibrosis (CF) 
and other cancers [9-11]. Other efflux pumps in the RND family such as MexA.B- 
OprM and MexC,D-OprJ are also found to be responsible for multidrug 
resistance in the gram-negative bacteria, Pseudomonas aeruginosa [12-17],
Fluorescent proteins [e.g., cyan fluorescent protein (CFP), green 
fluorescent protein (GFP), yellow fluorescent protein (YFP) and red fluorescent 
protein (RFP)] have been widely used to study those MDR transporters [18-20]. 
For example, green fluorescent protein (GFP) has been extensively used as 
reporter genes and fluorescence probes to study location, distribution and 
functions of proteins in live cells [21-23]. Fluorescent fusion proteins have been 
used to label the ABC transporter genes in Caenorhabditis elegans and to 
identify the locations of ABC transporters in fission yeast [24].
Compared to conventional fluorescent proteins as described above, 
nanometer sized particles such as quantum dots, noble metal nanoparticles
(NPs) (e.g., gold or silver NPs) or magnetic NPs have found their applications in 
the area of cancer nanotechnology due to their unique optical, magnetic and 
structural properties which are lacking as compared to biological molecules and 
bulk materials [25-31]. These properties give them unprecedented advantages 
for the diagnosis and treatment of cancer and other human diseases when they 
are conjugated with a variety of diagnostic (e.g., optical or magnetic) and 
therapeutic (e.g., anticancer drugs or other antibiotics) agents [26, 29, 32-36]. 
Recent advances are made available in applying NP based probes for molecular 
and cellular imaging [37-39], targeted cancer therapy [29, 40] as well as early 
screening and detection of cancer [25, 28, 31, 32, 41]. Among those nanometer 
sized particles, noble (Ag or Au) NPs have some unique features, such as size- 
and shape-dependent optical properties, a high surface area to volume ratio [37- 
39, 42-44]. These optical properties are mainly due to a phenomenon called 
localized surface plasmon resonance (LSPR), which is highly dependent upon 
their size, shape and surrounding environments. Besides, noble NPs exhibit 
strong Rayleigh scattering, allowing them to be directly observed and studied 
using dark-field optical microscopy and spectroscopy (DFOMS) systems [37-39, 
42-44]. All of these properties have made it possible for them to be very 
promising probes for exploring the unknown mechanisms of MDR transporters.
Though extensive studies have been done on the multi-drug resistance 
(MDR) transporters over the last two decades, there is still much controversy 
regarding the exact efflux mechanisms of many well-studied transporters such as 
PgP and MsbA [3, 5, 8, 45-48], Thus, it is still crucial to study their efflux
mechanisms by applying new research tools. The potential outcomes from these 
studies will serve as guidance for the development of effective therapeutic agents 
for combating those MDR caused diseases.
In this dissertation, I first created two new transgenic strains of Bacillus 
subtils (B. subtilis) by fusing EGFP with a ABC transporter called BmrA in gram- 
positive B. subtilis and expressed them in ABmrA strain [22]. Then, we 
characterized the efflux functions of those fusion strains by using both traditional 
fluorescence probes and novel nanoparticle optical probes. Next, we created and 
well characterized the efflux functions of a similar fusion strain by fusing EGFP to 
MexB antiporter gene and expressing the fusion gene in AMexB strain of 
Pseudomonas aeruginosa (P. aeruginosa), which is gram-negative bacteria and 
causes many MDR problems due to the existence of a major RND pump named 
MexA,B-OprM. After that, we took a step further by using antibiotics conjugated 
nanoparticles as both optical probes and drug carriers to study the toxicity and 
biocompatibility of nanoparticle based drug carriers. The obtained outcomes from 
those studies enriched our knowledge about the structures and functions of MDR 
transporters as well as offered new insights into the future designing of smart 
drug carriers to overcome the MDR related problems in terms of increasing 
targeting efficacy of therapeutic agents.
This dissertation is comprised of six chapters. In chapter I, we provide a 
general overview of the research background related to our studies as well as the 
outlines of contents of each chapter.
In Chapter II, in order to study the efflux mechanisms of those MDR 
transporters, we first need to light up them. Hence, this Chapter describes the 
molecular cloning and characterization of an EGFP fused ABC transporter 
(BmrA) in gram-positive Bacillus subtils [22], as illustrated in Fig. 1. We created 
two fusion strains by fusing EGFP with both C-terminus and N-terminus of BmrA 
gene (Fig. 1-A and B) and successfully expressed the fusion genes in ABmrA 
strain. We then characterized the efflux functions of those fusion strains and 
compared the results with the ones from using WT and ABmrA strains and 
determined that the two new fusion strains maintained the original efflux 
functions of BmrA transporter while the strain containing N-terminal fusion of 
EGFP with BmrA functions a little better than the other fusion strain.
In Chapter III, from a different perspective, we probed the efflux functions 
of the BmrA transporter in different B. subtilis strains including those EGFP fused 
BmrA strains by using 12 nm Ag NPs as single nanoparticle optical probes [37], 
as illustrated in Fig. 2. Our results indicated that 12nm Ag NPs are the substrates 
of this BmrA efflux pump. Besides, different strains showed different efflux 
kinetics of 12 nm Ag NPs. More specifically, we found ABmrA strain accumulated 
more intracellular NPs over time than WT or the two fusion strain did due to the 
lacking of BmrA transporter. Those results clearly suggested that the Ag NPs 
could also be the substrates of those MDR transporters, which makes it possible 
for us to use them to probe the efflux function kinetics over time owing to their 
unique physical and chemical properties.
In Chapters IV, to compare with the EGFP fused BmrA transporter in 
gram-positive Bacillus subtilis (Chapter II), we fused EGFP to the MexB part of 
MexA,B-OprM transporter in gram-negative Pseudomonas aeruginosa and well 
characterized the efflux functions of this new fusion strain, as illustrated in Fig. 3. 
Our results indicated that EGFP fused MexB antiporter only retained partial efflux 
functions of MexA,B-OprM efflux pump, which suggest possible steric hindrance 
effects resulting from either the fusion of EGFP with MexB or the assembly of a 
dysfunctional MexA,B-OprM efflux pump which contains three copies of each 
component of this efflux pump (MexA, MexB and OprM) on the inner and outer 
membranes of P. aeruginosa bacteria.
In Chapter V, in order to study the biocompatibility and toxicity of NPs as 
effective drug carriers, we conjugated silver NPs with the antibiotic (ofloxacin) 
and compared the size-dependent antibacterial effects of ofloxacin alone 
(absence of NPs) and various sized silver NPs conjugated ofloxacin in 
Pseudomonas aeruginosa, as illustrated in Fig. 4. Our results indicated that 
larger sized nano-carriers generated more potent antibacterial effects compared 
to smaller sized nano-carriers when the total amount of antibiotic molecules 
contained in all sized nano-carriers is the same. Those interesting results offered 
new insights into the future design of efficient drug carriers in the process of 
combating the MDR caused diseases.
In Chapter VI, we summarized our major research findings in those 







Fig. 1 Illustration of design and characterization of efflux functions of ABC- 
EGFP transporters in gram-positive Bacillus subtilis.
We fused EGFP to both C-terminus and N-terminus of BmrA gene and 
expressed fusion genes in ABmrA strain. Efflux functions of fusion strains were 
characterized by time course incorporation of fluorescence dye molecules and 
results suggested that both fusion strains maintained the original efflux functions 
of BmrA transporter. Modeling prediction of both fusion proteins indicated no 
steric hindrances effects of EGFP to BmrA protein. The individual BmrA 
monomers (light orange or yellow), AMP-PNP (red-white-blue spheres), and 
EGFP (green) are illustrated, respectively [22]
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Fig. 2 Illustration of transport of silver NPs across the cell membrane by a 
ABC transporter (BmrA) in gram-positive Bacillus subtilis.
We probed the efflux functions of different B. subtilis strains with different 
expression level of BmrA proteins by transport of Ag NPs based single plasmonic 
optical probes across the cell membrane. Results indicated that accumulation 
and efflux kinetics of intracellular NPs for single living cells depended upon the 
cellular expression level of BmrA, NP concentrations, and a pump inhibitor 
(orthovanadate), suggesting that NPs are substrates of BmrA transporters and 
the passive diffusion driven by concentration gradients is the primary mechanism 
for NPs to enter the cells. The functional BmrA transporter is illustrated as 
combination of two BmrA monomers with each monomer containing a nucleotide 
binding domain (A) and a transmembrane domain (T). Ag NPs are illustrated as 
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Fig. 3 Illustration o f design and characterization o f efflux functions o f RND- 
EGFP transporters in gram-negative Pseudomonas aeruginosa.
We fused EGFP to N-terminus of mexB gene and expressed the fusion gene in 
AMexB strain. Efflux functions of fusion strains were characterized by both time 
course incorporation of fluorescence dye molecules and measurement of MICs of 
selected antibiotics. Results suggested that the fusion strain partially retained the 
original efflux functions of MexA,B-OprM transporter. Modeling prediction of the 
fusion protein indicated possible steric hindrances effects of EGFP fused to 
MexB, which may lead to dysfunctional assembly of MexA.B-OprM transporter 
across the cell membrane. The membrane fusion protein MexA (turquoise), outer 
membrane channel OprM (violet), the individual antiporter MexB monomers (red, 
orange, and light brown) and EGFP (green) are illustrated, respectively [8]
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Fig. 4 Illustration of study of size-dependent antimicrobial effects of nano­
carriers on gram-negative bacteria, Pseudomonas aeruginosa.
We synthesized and characterized three sized Ag NPs conjugated with drug 
molecules and we studied the antimicrobial effects of these nano-carriers on the 
growth of bacteria in P. aeruginosa. We found the size-dependent inhibitory 
effects of these nano-carriers on the growth of bacteria, with larger nano-carriers 
conferring higher antimicrobial effects than smaller ones at the same 
concentration of conjugated drug molecules on their surfaces. Ag NPs of different 
sizes (2.4, 13.0 and 92.6 nm) are illustrated as blue, green and red spheres, 
respectively. Molecular structure of ofloxacin is shown above and ofloxacin in 
different sized Ag carriers is represented by 4-point star ( ^ )
CHAPTER II
DESIGN AND PROBING OF EFFLUX FUNCTIONS OF EGFP FUSED 
ABC MEMBRANE TRANSPORTERS IN GRAM-POSITIVE BACTERIAL 
CELLS USING FLUORESCENCE SPECTROSCOPY
INTRODUCTION
ABC (ATP-binding cassette) transporters exist in all live organisms, 
ranging from bacteria to human [1, 49-53]. They are involved in the unidirectional 
transport, either import or export, of a wide variety of structurally and functionally 
unrelated substrates, including ions, sugars, lipids, amino-acids, proteins, or 
xenobiotics, against substrate concentration gradients [1, 49-54]. Such function is 
responsible for multidrug resistance (MDR) in bacteria and cancer cells. In 
bacteria, ABC transporters constitute the largest protein family. For instance, 78 
ABC transporters have been reported in B. subtilis [55, 56]. Notably, 48 ABC 
transporters have been identified in human. Abnormal functioning of some of 
these ABC transporters in human is directly responsible for severe pathologies 
[10]. For example, P-glycoprotein, the first mammalian ABC transporter 
identified, accounts for MDR in cancer cells, which leads to ineffective therapy. 
Cystic fibrosis is caused by mutations in the chloride channel of cystic fibrosis 
transmembrane regulator [9-11],
Interestingly, all ABC transporters share a common organization, which 
consists of four core domains: two transmembrane domains (TMD) and two 
nucleotide-binding domains (NBD) [46, 52, 57-61]. The TMDs are quite variable
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in sequence and topology, which defines the substrate binding sites and forms 
the transport passageway for substrates to cross the membrane. In contrast, the 
NBDs show conserved sequences, which empower the transporters by binding 
and hydrolyzing ATP [46, 57, 61, 62]. These four domains are either fused as a 
single polypeptide or present in two to four separate polypeptides. Three- 
dimensional (3D) structures of many NBDs isolated from various origins share 
the same global topology, suggesting a common evolutionary origin and similar 
mechanisms of energy coupling in all ABC transporters [52,62],
Despite extensive studies, their translocation mechanisms remain elusive 
[9, 52]. Many fundamental questions about molecular mechanisms and 
interactions of multidrug ABC transporters (efflux pumps) remain unanswered [9, 
52, 62]. For example, one major question is how to identify the individual 
integrated steps of the catalytic cycle, which are responsible for substrate 
translocation. Notably, fusion of ABC membrane transporters with EGFP offers 
the opportunity to visualize membrane transporters and to study their interactions 
with substrates that lead to their translocations. However, the fusion of ABC 
transporters with EGFP may alter their efflux function. Thus, it is crucial to first 
characterize the efflux function of ABC-EGFP transporters, prior to using them to 
probe their molecular mechanisms.
Fluorescent proteins (e.g., GFP) have been widely used as reporter genes 
and non-invasive fluorescence probes for study of molecular mechanisms and 
functions of proteins in live cells [20, 63]. Promoter-fluorescent protein fusions 
have been used to identify the ABC transporter genes in Caenorhabditis e/egans
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and to determine the locations of ABC transporters in fission yeast [24, 64]. GFP 
has been used as a fluorescence probe to characterize the topologies of ABC 
transporters, because GFP fluoresces in the cytoplasmic space (reducing 
environment), but not in the periplasm or plasma membrane [65, 66], Studies 
have shown that GFP fusion proteins (membrane transporters) may alter the 
function of proteins [67, 66]. Unfortunately, the functions of GFP fused proteins 
(transporters) have not yet been widely characterized and compared with the 
non-fused proteins.
Currently, structures of membrane transporters are characterized by X-ray 
crystallography, which is limited by the difficulties of crystallization of membrane 
proteins. It is also unable to provide real-time kinetic information about the 
molecular mechanisms and conformation change of ABC transporters.
The primary methods for study of multidrug membrane transporters in 
bacterial and mammalian cells include the measurement of their accumulation of 
radioactively labeled substrates (14C and 3H) and the fluorescence dyes (e.g., 
rhodamine 123, Fluo-3, Hoechst dyes) [54, 68-76]. Fluorescent dyes, such as 
Hoechst dyes and ethidium bromide (EtBr), emit weak fluorescence in aqueous 
solution (outside cells) and become strongly fluorescent in non-polar and 
hydrophobic environments, especially as the dye molecules enter cells and 
intercalate with DNA [77]. Thus, time-dependent (time-course) fluorescence 
intensity of the dyes is particularly suitable for real-time monitoring of the 
accumulation of substrates in bacterial and mammalian cells and for study of 
multidrug transporters in live cells [54, 68-76].
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Efflux function of multidrug membrane transporters has also been 
characterized by determining the minimal inhibitory concentrations (MICs) of 
drugs (e.g., antibiotics) that are specific substrates of the transporters and show 
the specific susceptibility toward given strains of bacterial cells [78, 79]. 
Unfortunately, to our knowledge, antibiotics that are specific substrates of BmrA 
membrane transporter and show specific susceptibility for BmrA cells, but not 
ABmrA cells, have not yet been identified. Thus, MIC method has not yet been 
used to characterize BmrA transporter.
In this study, we constructed two fusion proteins by fusing either C- or N- 
terminal BmrA gene with EGFP vectors, and expressing them in ABmrA cells to 
produce two new strains of B. subtilis. To determine whether BmrA-EGFP 
transporters retain the efflux function of BmrA, we characterized their efflux 
kinetics of fluorescence molecules (Hoechst 33342), and their dependence on 
the expression of BmrA and the presence of a pump inhibitor (orthovanadate) 
using fluorescence spectroscopy. To our knowledge, BmrA-EGFP transporters in 
B. subtilis have not yet been reported. These new strains are needed for study of 
functions and structures of BmrA transporter in single live cells.
RESULTS AND DISCUSSION
Construction and characterization of BmrA-EGFP fusion genes and their 
expression
We designed and constructed bmrA-EGFP fusion genes by fusing the C- 
terminal or N-terminal bmrA genes with EGFP vectors. The fusion genes,
pSG1154-BmrA (54A) and pSG1729-BmrA (29A), were constructed as shown in 
Fig. 5 and as described in Experimental Section. The pET23-BmrA plasmid was 
amplified using two sets of primers, C-terminal (CP1, CP2) or N-terminal (NP1, 
NP2) primers, via PCR. The amplified PCR products and vectors (pSG1154 and 
pSG1729) were then digested using a pair of restriction endonuclease enzymes 
(XhoUEcoRl). The digested and purified PRC products (1800 base pairs, bp, 
bmrA genes) were finally ligated with the digested and purified vectors (7600 bp), 
pSG1154 or pSG1729, respectively. This approach enables us to insert the bmrA 
gene into each vector via fusion of C-terminal or N-terminal bmrA genes with 
EGFP gene, and to create two fusion genes (pSG1154-BmrA and pSG1729- 
BmrA), respectively.
The amplified PCR products in Fig. 5 were characterized using gel 
electrophoresis and DNA sequencing. The results in Fig. 6A show that both PCR 
products of pET23-BmrA plasmid amplified by using C-terminal and N-terminal 
primers are 1, 800 bp, which agrees well with the number of base pair of the 
bmrA gene [80]. The fusion genes digested by a pair of restriction endonuclease 
enzymes (Xho\ / EcoRI) (Fig. 6B) show the products of 7, 600 bp and 1, 800 bp, 
which agree well with that of digested vectors and bmrA genes [18, 80], 
respectively. The DNA sequencing results (sequence data not shown) of both 
fusion genes show that the sequences of bmrA gene are in excellent agreement 
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pSGl 729-bmrA (294. Nt-bmrA-EGFP)
Fig. 5 Schematic illustrations of construction of (A) Ct-bmrA-EGFP and (B) 
Nt-bmrA-EGFP fusion genes.
The plasmid (pET23-BmrA) was amplified using two pairs of primers (CP1 and 
CP2, or NP1 and NP2) by PCR, respectively. The amplified genes and vectors 
(pSG1154 or pSG1729) were digested by restriction enzymes (Xhol/ EcoRl). The 
digested genes were ligated to the digested vectors, generating pSG1154-BmrA 
(54A, Ct-bmrA-EGFP’) and pSG1729-BmrA (29A, Nt-bmrA-EGFP) fusion genes, 
respectively
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Fig. 6 Characterization of bmrA-EGFP fusion genes using agarose gel 
electrophoresis.
(A) L1: DNA markers/ladders in base pair (bp); L2: bmrA gene amplified using 
the plasmid (pET23-BmrA) as a template and CP1 or CP2 as primers (PCR 
Product I in Fig. 5); L3: bmrA gene amplified using the plasmid (pET23-BmrA) as 
a template and NP1 or NP2 as primers (PCR Product II in Fig. 5). Arrows point to 
the PCR products of 1,800 bp, which agrees with the number of base pairs of 
bmrA genes. (B) L1: DNA markers in bp; L2: pSG1729-BmrA; L3: pSG1154- 
BmrA; L4: pSG1729, and L5: pSG1154, digested by Xhol/EcoR, respectively. 
Arrows point to the digested vector plasmids at 7,600 bp and bmrA genes at 
1,800 bp
Fig. 7 Characterization of expression of bmrA-EGFP fusion genes in 
ABmrA cells.
(A) Dark-field optical images and (B) green fluorescence images of single live 
cells: (a) Nt-BmrA-EGFP; (b) Ct-BmrAEGFP; (c) WT-BmrA; and (d) ABmrA 
strains, respectively. The intensity scales are 55-355 ADC (analog and digital 
counts) in (A) and 55-95 ADC in (B) Scale bar = 5 pm
We transformed the fusion gene (pSG1154-BmrA or pSG1729-BmrA) into 
ABmrA cells to create two new strains of B. subtilis (Ct-BmrA-EGFP and Nt- 
BmrA-EGFP cells). Their expression in single live cells was characterized by 
measuring fluorescence of EGFP in single live cells using fluorescence 
microscopy and spectroscopy. The results in Fig. 7 show that all Ct-BmrA-EGFP
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and Nt-BmrA-EGFP cells, but none of BmrA and ABmrA cells, emit green 
fluorescence, which demonstrates the successful expression of fusion genes in 
the cells.
Notably, these two new strains offer the possibility of characterization of 
locations, topologies and functions of BmrA membrane transporters in live cells, 
as those reported for other ABC transporters [65-67, 81]. For instance, fusion of 
EGFP with BmrA enables one to probe the locations and topologies of BmrA and 
the translocation of pump substrates (efflux function) of BmrA in live cells in real 
time. However, BmrA-EGFP transporters must first be characterized to determine 
whether they retain the original efflux functions of BmrA, prior to their uses for 
study of functions and structures of BmrA.
Study of suitability of fluorescence molecules for probing of efflux kinetics 
of transporters in live cells
Hoechst dyes are well known substrates of ABC membrane transporters 
and have been used to monitor the accumulation and efflux kinetics of the BmrA 
transporter embedded in vesicles [54, 76]. Notably, Hoechst molecules emit 
week fluorescence in aqueous solution (outside the cells), and their fluorescence 
intensity increases substantially (up to 10-fold), as they enter into the cells and 
intercalate with DNA [77], Thus, the fluorescence intensity of the dye molecules 
can be used to measure the accumulation and efflux kinetics of membrane 
transporters in live cells in real time.
To determine whether time-dependent fluorescence intensity of the dye 
molecules acquired at the peak wavelength (Amax) of 450 nm is suitable for 
monitoring their accumulation kinetics in live cells in real time, we acquired the 
fluorescence spectra of the dye molecules incubated with the live cells (Ct-BmrA- 
EGFP, Nt-BmrA-EGFP, WT, ABmrA cells) over time. The representative results 
in Fig. 8A show that the Amax of its emission spectra at 450 nm remains 
essentially unchanged over time, and its fluorescence intensity increases with 
time. The results show that intercalation of dye molecules with intracellular DNA 
in live cells did not lead to the shift of Amax of their excitation and emission 
spectra, and the presence of EGFP did not affect fluorescence measurements of 
the dye molecules.
To determine whether photodecomposition of the dye molecules could 
significantly affect their fluorescence intensity over time, we measured the 
excitation and emission spectra of the dye molecules incubated with the live cells 
that had been constantly irradiated by the excitation beam (350 nm) or kept in the 
dark for 30 min. The results in Fig. 8B show that the fluorescence intensity and 
Amax of the excitation and emission spectra for the exposed and unexposed 
samples are nearly identical.
Taken together, the results in Fig. 8 show that the time-dependent 
fluorescence intensity of the dye molecules incubated with live cells at 450 nm is 
well suited for monitoring of their accumulation kinetics in live cells using 
fluorescence spectroscopy. By probing of dependence of their accumulation 
kinetics on the expression level of BmrA in each strain, we can characterize the
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efflux function of BmrA and BmrA-EGFP transporters in live cells and determine 
whether BmrA-EGFP retains the efflux function of BmrA.
Probing of dependence of efflux kinetics of transporters on their 
expression in live cells
To determine whether BmrA-EGFP proteins expressed in ABmrA cells 
retain the efflux function of BmrA transporter, we studied the efflux kinetics of 
membrane transporters in live cells in real time using the fluorescence probe 
(Hoechst 33342). The studies were performed in the absence and presence of 
glucose, aiming to determine the roles of glucose on the efflux function of BmrA 
in live cells. It is worthy noting that previous studies for probing of accumulation 
and efflux kinetics of the dye molecules for ABC transporters were carried out in 
the presence of glucose [54, 76]. Notably, the potential effects of the glucose on 
the accumulation and efflux function of ABC transporters were not studied.
The results in Fig. 9A show that, in the absence of glucose, the 
fluorescence intensity of the dye molecules increases with time, indicating that 
the dye molecules enter the cells and intercalate with intracellular DNA. Notably, 
the accumulation rates (slope of the each curve) highly depend upon the 
expression level of BmrA in the cells. ABmrA cells (deletion of BmrA) show the 
highest accumulation rates with the highest fluorescence intensity at each given 

















Fig. 8 Characterization of fluorescence properties of Hoechst dye 
molecules for probing the efflux kinetics of BmrA and BmrA-EGFP 
membrane transporters in live cells (Ct-BmrA-EGFP or Nt-BmrA-EGFP).
(A) Fluorescence emission spectra of the dye molecules (2 pM) incubated with 
the cells ( O D 6oonm = 0.1) at (a) 5, (b) 200, and (c) 400 s, show that the peak 
wavelength of the spectra (Amax = 450 nm) remains essentially unchanged, while 
fluorescence intensity increases with time. (B) Excitation and emission spectra of 
the dye molecules (2 pM) incubated with the cells that: (a) and (b) had been 
exposed to 350 nm excitation beam for 30 min; and (c) and (d) in the dark, show 
that the fluorescence intensity and Amax of the spectra of both samples are nearly 
identical
22
Both Nt-BmrA-EGFP and Ct-BmrA-EGFP cells (over expression of BmrA) 
show the lower accumulation rates than ABmrA, suggesting that both BmrA- 
EGFP cells extrude the intracellular dye molecules which lead to the lower 
accumulation rates. Notably, Nt-BmrA-EGFP cells have slightly higher 
accumulation rates than BmrA cells, but much lower accumulation rates than Ct- 
BmrA-EGFP cells. The results suggest that fusion of either N-terminal or C- 
terminal BmrA with EGFP retains efflux function of BmrA, with less steric effect of 
EGFP on N-terminal fusion.
In the presence of glucose (Fig. 9B), ABmrA cells display the highest 
accumulation rates with the highest intracellular dye molecules, both Ct-BmrA- 
EGFP and Nt-BmrA-EGFP cells show the lowest rates with the lowest amount of 
the intracellular dye molecule. Interestingly, the BmrA cells show higher 
accumulation rates with higher amount of intracellular dye molecules than BmrA- 
EGFP cells. The results show that the presence of glucose leads to three orders 
of magnitude higher accumulation rates and higher amount of intracellular dye 
molecules in a shorter period of time than the absence of glucose. The 
quantitative results of Fig. 9 are summarized in Table 1.
Taken together, the results in Fig. 9 indicate that the presence of glucose 
affects the study of the efflux function of BmrA and BmrA-EGFP transporters 
using the dye molecules via fluorescence spectroscopy. The results suggest 
drastic effects of glucose upon the accumulation and efflux of the dye molecules 
by live cells. Further studies are underway to determine the roles of glucose in 























Fig. 9 Study of the dependence of accumulation and efflux kinetics of the 
intracellular dye molecules on the expression of BmrA and BmrA-EGFP 
transporters in live cells.
Time-dependent fluorescence intensity of the dye molecules (2 pM) incubated 
with cells (O D e o o n m  = 0.1): (a) ABmrA, (b) Ct-BmrA-EGFP, (c) WT (BmrA), and 
(d) Nt-BmrA-EGFP strains, in (A) absence and (B) presence of 25 mM glucose
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Inhibitory effects of a pump inhibitor on efflux kinetics of transporters in 
live cells
To determine whether BmrA and BmrA-EGFP membrane transporters are 
specifically responsible for the efflux of the dye molecules out of the cells, we 
studied the accumulation kinetics of the intracellular dye molecules in live cells 
(WT BmrA, Nt-BmrA-EGFP, Ct-BmrA-EGFP, ABmrA cells) in the presence of a 
pump (ATPase) inhibitor, orthovanadate [82, 83], using fluorescence 
spectroscopy.
The results in Fig. 10a show, in the absence of the glucose, the lower 
accumulation rates and the lower amount of the intracellular dye molecules were 
found in the cells (WT, Nt-BmrA-EGFP, Ct-BmrA-EGFP strain) in the absence of 
orthovanadate (Fig. 10A-C, a, i) than its presence (Fig. 10A-C, a, ii), respectively. 
In contrast, the accumulation rates and amount of the intracellular dye molecules 
for ABmrA cells remain nearly unchanged in the absence (Fig. 10D, a, i) and the 
presence of the orthovanadate (Fig. 10D, a, ii). This experiment serves as a 
control, which demonstrates that orthovanadate at the given dose used in this 
study specifically inhibits the efflux function of BmrA transporter, but not other 
membrane transporters in the cells.
These results show the inhibitory effects of the pump inhibitor on the efflux 
function of BmrA and BmrA-EGFP, suggesting that BmrA and BmrA-EGFP 
transporters are indeed responsible for the extrusion of the dye molecules out of 
the cells, which lead to the lower accumulation rates than ABmrA. Interestingly, 
the less inhibitory effects of orthovanadate on efflux of the dye molecules by Nt-
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BmrA-EGFP than Ct-BmrA-EGFP (Fig. 10B-C, a) were observed. The plausible 
explanation may be that either high amount of orthovanadate are needed to 
inhibit the efflux function of Nt-BmrA-EGFP or the N-terminal fusion is less 
sensitive to the inhibitory effect of orthovanadate than C-terminal fusion. Further 
studies are needed to depict the detailed mechanisms.
Interestingly, in the presence of glucose, the accumulation rates of the dye 
molecules and their accumulation amount in all four strains remain essentially 
unchanged in the presence and absence of orthovanadate, as shown in Fig. 10b, 
respectively.
Notably, the accumulation rates of the intracellular dye molecules are 
much lower in the absence of glucose (Fig. 10a) than its presence (Fig. 10b). 
The quantitative analysis of accumulation rates in Fig. 10 are summarized in 
Table 1. The results suggest that the effects of glucose on the accumulation and 
efflux of the dye molecules in live cells are higher than the inhibitory effects of 
orthovanadate. Thus, in the presence of glucose, we observed no inhibitory 
effects of orthovanadate.
Taken together, these results (Fig. 10) show the inhibitory effect of 
orthovanadate upon efflux function of BmrA and BmrA-EGFP transporters and 
suggest that they are responsible for efflux of the dye molecules out of the cells. 
Thus, BmrA-EGFP retains the efflux function of the BmrA. The results also show 
the drastic effects of glucose upon the efflux of intracellular dye molecules by the 
transporters in live cells, suggesting that efflux function of ABC transporters must 
be characterized in the absence of glucose.
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WT Ctc Ntd ABmrA
0 0 3.8 x10 3 1.1 x10'2 5.1 xIO"’* 3.1 x102
0 25 2.2 x10 2 2.5x1 O'2 1.6 x10'2 3.1 x1 O'2
25 0 1.1 0.6 0.5 1.0
25 25 1.1 0.7 0.8 1.4
a Orthovanadate
b Rate = slopes of the curves at its half equilibrium time. The equilibrium time is 
defined at the time that the fluorescence intensity reaches the maximum and 
remains essentially unchanged.
c Ct-BmrA-EGFP: cells with the over-expression of C-terminal BmrA fused with 
EGFP
d Nt-BmrA-EGFP: cells with the over-expression of N-terminal BmrA fused with 
EGFP
Structural Modeling and Analysis of Fusion BmrA-EGFP Transporters
The results in Figs. 9A and 10a show that Ct-BmrA-EGFP and Nt-BmrA- 
EGFP transporters extrude the intracellular dye molecules and their efflux 











































Fig. 10 Probing of inhibitory effects of a pump inhibitor (orthovanadate) on 
efflux function of BmrA and BmrA-EGFP transporters.
Time-dependent fluorescence (FL) intensity of the dye molecules (2 pM) 
incubated with the cells (ODeoonm = 0.1): (A) WT (BmrA), (B) Ct-BmrA-EGFP, (C) 
Nt-BmrA-EGFP, and (D) ABmrA, in (a) absence and (b) presence of glucose (25 
mM) and (i) without and (ii) with orthovanadate (25 pM). Note that the initial 
fluorescence intensity in Fig. 10D-a varies slightly, which is attributed to the slight 
variation of cell concentrations
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that the fusion proteins retain efflux function of BmrA. The results show that Nt- 
BmrA-EGFP transporter exhibits the higher efflux rates (lower accumulation 
rates) than Ct-BmrA-EGFP, indicating that EGFP contributes less hindrance to 
the efflux function of Nt-BmrA-EGFP than Ct-BmrA-EGFP transporter.
To better understand these interesting findings, we modeled Ct-BmrA- 
EGFP and Nt-BmrA-EGFP, as described in experimental and model section. We 
used SWISS-MODEL to assemble EGPF and BmrA models using available 3D 
structures of GFP (PDB-code: 3ogo) with a sequence identity of 98.7%; and 
homologous structural models of the ‘closed’ multidrug ABC transporter Sav1866 
and LmrA with up to 33.7 % sequence identity (PDB-codes: 2onj, 2hyd, 1mv5) 
[84, 85], respectively. The secondary structures of the truncated regions 
connecting the EGFP to BmrA were analyzed by PSIPRED server [86]. The 
results (Fig. 11A-B) show that the linker regions are unstructured and 
conformationally flexible.
The model of Ct-BmrA-EGFP dimer in Fig. 11C shows that the EGFP 
situates at the top of the ATP-binding domain (NBD) of the BmrA transporter. In 
contrast, the model of Nt-BmrA-EGFP dimer in Fig. 11D depicts that the EGFP 
protrudes sideways from the TMDs. We observed fluorescence of EGFP for both 
fusion strains, indicating that the EGFP was located in the cytoplasm, but not in 
the cellular plasma membrane (next to the TMD). Studies have shown that, in 
contrast to cellular plasma membranes, the cytoplasmic space offers the required 
reducing conditions, which enable the EGFP to fluoresce [65].
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Fig. 11 Illustrations of modeled structures of Ct-BmrA-EGFP and Nt-BmrA-
EGFP proteins expressed in ABmrA cells.
Secondary structures o f the fusing regions of (A) N- and (B) C-terminal BmrA 
with EGFP show unstructured and highly flexible linker regions. (C) Ct-BmrA-
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EGFP dimer model shows the EGFP domains on the top of the ATP-binding 
domains (NBDs). (D) Nt-BmrA-EGFP dimmer model shows the EGFP domains 
protruding sidewards of transmembrane domains (TMDs). The individual BmrA 
monomers in light orange or yellow, AMPPNP in red-white-blue spheres, and 
EGFP in green are illustrated
Both structures show that the EGFP is linked to BmrA via a long 
unstructured loop region comprised of 19 amino acids for the Ct-BmrA-EGFP 
and 23 amino acids for the Nt-BmrA-EGFP, respectively. Such highly flexible 
linker regions allow substantial mobility of the EGFP molecule in the positional 
placement in relation to the BmrA transporter. Thus, EGFP does not create 
significant obstruction to the BmrA in either fusion proteins. Nonetheless, the 
structure of Ct-BmrA-EGFP dimer (Fig. 11C) shows the closer proximity (-14 A) 
of two C-termini of BmrA in the “closed” dimer. Thereby, it may result in 
additional interference of EGFP with the function of BmrA, as BmrA converts 
from the ‘open’ to the ‘closed’ conformation during the substrate transport cycle. 
In contrast, the structure of Nt-BmrA-EGFP dimer (Fig. 11D) illustrates that the 
distance between two N-termini of BmrA in the “closed” dimer is 47.9 A, which is 
larger than that of C-terminal fusion, suggesting less interference of N-terminal 
fusion of BmrA with EGFP.
Taken together, this structural analysis provides interesting evidence to 
explain why Ct-BmrA-EGFP and Nt-BmrA-EGFP transporters retain the efflux
31
function of BmrA, and why Nt-BmrA-EGFP is more favorable for the efflux 
substrate translocation than Ct-BmrA-EGFP.
SUMMARY
In summary, we have designed and constructed bmrA-EGFP fusion genes 
and successfully expressed them in ABmrA cells to generate two new strains of 
B. subtilis (Ct-BmrA-EGFP and Nt-BmrA-EGFP). We studied the dependence of 
accumulation kinetics of intracellular fluorescence molecules (Hoechst 33342, a 
pump substrate) on the expression level of BmrA and BmrA-EGFP transporters 
for each strain (WT, ABmrA, Ct-BmrA-EGFP, Nt-BmrA-EGFP), by measuring the 
time-dependent fluorescence intensity of the intracellular dye molecules using 
fluorescence spectroscopy. We found that either Ct-BmrA-EGFP or Nt-BmrA- 
EGFP extruded the pump substrate, leading to the lower accumulation of the 
intracellular dye molecules than ABmrA. The results suggest that the fusion 
proteins retain the efflux function of BmrA. Notably, Nt-BmrA-EGFP extruded the 
intracellular dye molecules more rapidly than Ct-BmrA-EGFP. Our structural 
analysis shows the highly flexible linker regions connecting EGFP with BmrA in 
the fusion proteins, suggesting a minimal obstruction of EGFP to the BmrA. 
Nonetheless, two C-termini of the “close” dimer of BmrA is in closer proximity (14 
A) than two N-termini of the dimer (47.9 A), which suggests the less steric effect 
of the N-terminal BmrA fusion on its efflux function than the C-terminal fusion. 
The efflux function of both BmrA-EGFP transporters was inhibited by the ABC 
pump inhibitor (orthovanadate), which further demonstrated that both fusion
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pumps retain the efflux function of BmrA transporter. This study also shows that 
the presence of glucose affects the accumulation and efflux of the dye molecules 
by the transporters in live cells using fluorescence spectroscopy. Thus, the efflux 
function of ABC transporters must be characterized in the absence of glucose.
METHODS
Reagents and cell strains
Escherichia coli DH5a (Invitrogen), PCR polymerase (Agilent 
Technologies), plasmid isolation kit (Qiagen), DNA gel extraction kit (Qiagen), 
DNA ligation kit (T4 DNA ligase and ligation buffer) (Roche), XhoUEcoRl (NEB), 
tetracycline (Calbiochem), spectinomycin (Enzo), xylose (Spectrum), 
orthovanadate (Sigma), Hoechst 33342 (Invitrogen), casamino acid (BD), 
tryptose blood agar base powder (BD), B. subtilis strain (1A772, WT BmrA) and 
plasmids (pSG1154 and pSG1729) from Bacillus Genome Stock Center (BGSC) 
[18], were purchased and used as received. ABmrA and plasmid (pET23-bmrA) 
were provided by J. M. Jault [54].
All other media and cell culture plates were prepared in our lab. Medium A 
(100 mL) was prepared by mixing 10x Medium A base (10 mL) and 10x Bacillus 
salts (9 mL) in the sterilized Dl water. Medium B were prepared by mixing 
Medium A (10 mL), CaCI2 (0.1 mL, 50 mM) and MgCI2 (0.1 mL, 0.25 mM). The 
10x Media A base (1 L) was prepared by mixing yeast extract (10 g), casamino 
acids (2 g) and glucose (100 mL, 50%) in Dl water. The 10x Bacillus salts (1 L) 
was prepared by dissolving (NH4)2SQ4 (20 g), K2HP04-3H20  (183 g), KH2PQ4
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(60 g), sodium citrate (10 g), and MgS04-7H20  (2 g) in Dl water. The tryptose 
blood agar base plate was prepared by mixing tryptose blood agar base powder 
(3.3 g) in Dl water (100 ml_), which was then autoclaved, cooled to 45-50 °C, and 
mixed with sterile defibrinated blood (50 ml_). The mixture was immediately used 
to prepare the plates.
Cell culture and assay
Four B. subtilis strains (WT-BmrA, Ct-BmrA-EGFP, Nt-BmrA-EGFP, and 
ABmrA cells) were pre-cultured by inoculating single clones of each strain from 
the tryptose blood agar plates into each flask containing LB medium (1% 
tryptone, 0.5% yeast extract and 0.5% NaCI, pH 7.2). The flasks were placed in a 
shaker (LabLine Orbit-Environ, 37°C, 150 rpm) for 12 h. The cells were then 
cultured in the medium for another 8 h, WT and ABmrA in LB medium and Ct- 
BmrA-EGFP and Nt-BmrA-EGFP cells in LB medium with 1% xylose. The 
cultured cells were harvested and washed three times with PBS buffer using 
centrifugation (Beckman J2-21, JA-14, 6000 rpm). The washed cells re- 
suspended in the buffer (ODeoonm = 0.1) were used to study the accumulation 
kinetics of the fluorescence dye (Hoechst 33342) in the cells using fluorescence 
spectroscopy.
Construction and characterization of bmrA-EGFP fusion genes
We fused C-terminal bmrA gene with N-terminus EGFP (pSG1154) or N- 
terminal bmrA gene with C-terminus EGFP (pSG1729) in each vector to
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construct two fusion genes, Ct-bmrA-EGFP (pSG1154-BmrA) and Nt-bmrA- 
EGFP (pSG1729-BmrA) genes (Fig. 5), respectively. We named them as 54A 
and 29A, respectively.
The pET23-BmrA plasmid was used as a template, and two pairs of 
primers (CP1 and CP2 or NP1 and NP2) were used to amplify the bmrA gene 
using PCR to generate PCR product I and II (Fig. 6). The sequences of the 
primers are CP1 (5’-GCG CGC TCG AGG GAG GAA AAT ATA TGC CAA CCA 
AGA AAC AAA-3’); CP2 (5’-GCG CGG AAT TCC CCG GCT TTG TTT TCT 
AAG-3’); NP1 (5 - GCG CGC TCG AGA TGC CAA CCA AGA AAC AAA-3’); and 
NP2 (5-GCG CGG AAT TCT TAC CCG GCT TTG TTT-3’).
Each PCR product and vector (pSG1154 or pSG1729) was digested by a 
pair of restriction enzymes (XhoMEcoR\) by incubating the PCR product (10 ng) 
or the vector (5 ng), with two units of Xho\/EcoR\, in the digestion buffer (40 or 30 
pL) at 37 °C for 3 h. The digested products were characterized using agarose gel 
electrophoresis (0.8%, 8-10 V/cm) and purified using the gel extraction kit. The 
digested and purified PCR product I or II (20 nM) were ligated into the digested 
and purified vector (pSG1154 or pSG1729, 5 nM) in T4 DNA ligase (one unit in 
20 pL ligation buffer) at 12 °C overnight, respectively,
Each ligated product was transformed into DH5a competent cells 
(Invitrogen), as described previously [87, 88], Briefly, the ligated solution (10 pL) 
with the competent cell suspension (100 pL, ~2x107cells/ml_) was mixed and 
placed on ice for 30 min. The mixture was heated at 42 °C for 90 s and then 
placed on the ice for another 2 min. The LB media (1 mL) was added into the
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mixture, which was incubated in the shaker (37 °C, 150 rpm) for 1 h. 
Transformed cells were then harvested using centrifugation and suspended in 
the fresh medium, which was then inoculated onto LB plates and incubated at 37 
°C for 24 hours.
The clones from each plate were inoculated into the LB medium (3 mL) 
containing 100 pg/mL ampicillin and cultured in the shaker (150 rpm, 37 °C) for 
24 h. The plasmid (fusion genes) of each clone was isolated and amplified by 
PCR. The amplified PCR products were characterized using the restriction 
enzymes (XhoUEcoR\), gel electrophoresis, and DNA sequencing (Applied 
Biosystem, 3730x1 DNA Analyzer), to verify successful construction of fusion 
genes.
Characterization of expression of fusion genes in single live cells
Each characterized fusion plasmid was transformed into ABmrA cells 
using a previously reported protocol [87, 88], Briefly, the ABmrA cell plates were 
prepared by inoculating the cells onto the tryptose blood agar base plates and 
incubating them at 37 °C overnight. The clones on the plates were inoculated into 
Medium A (4.5 mL). The cell suspension (ODesonm = 0.1) was incubated in the 
shaker (37 °C, 150 rpm) for 3 h. The cell growth was followed over time. The 
number of the cells increased with time slowly for 40 min, then logarithmically for 
50 min and slowly again for another 90 min.
By then, the cell suspension (50 pL) was transferred into pre-warmed 
Medium B (0.45 mL) and cultured in the shaker (37 °C, 150 rpm) for 90 min. The
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fusion plasmid (pSG1154-bmrA or pSG1729-bmrA, 1 pg) was then added into 
the cell suspension and incubated in the shaker (37 °C, 150 rpm) for 30 min. 
Each aliquot of the transformants (200 pL for each plate) was spread onto the LB 
agar plate and incubated at 37 °C for 24 h. The clones were picked and cultured, 
as described above.
The starch-iodine assay was used to confirm the insertions of bmrA-EGFP 
fusion genes into the chromosome via double crossover events at the amyE site, 
as described in the following. Transformants were patched onto the LB agar 
plates containing 1% (w/v) starch, tetracycline (5 pg/mL) and spectinomycin (50 
pg/mL). The plates were incubated at 37 °C over night and stained by vaporizing 
a few iodine crystals in the inverted plate lids. The blue clones stained by the 
iodine had their amylase deficient phenotypes, which were correct constructs. 
The insertions of fusion genes into the chromosome amyE locus had led to the 
disruption of the amyE gene and dysfunctional AmyE protein, which could not 
disintegrate the starch.
Note that AmyE protein (a-amylase) can break down starch into small 
structural units (e.g., maltotriose and maltose). Thereby, the presence of AmyE 
protein would have failed the starch-iodine test (colorless). The clones showed 
blue in the starch-iodine test, confirming the successful insertion of each BmrA- 
EGFP fusion gene into the chromosomal amyE locus. Furthermore, these two 
new strains fully grew in the medium, and reached confluent at the same time as 
WT-BmrA and ABmrA strains. The results suggest non-clonal effects.
37
The expression of fusion genes in single live cells was characterized by 
measuring fluorescence of EGFP. The cell suspension in the PBS buffer were 
imaged in a micro-chamber using dark-field optical and epi-fiuorescence 
microscope (Nikon, E-400), equipped with a CCD camera (Micromax, Roper 
Scientific). We have fully described the design and construction of the micro­
chamber and dark-field optical and epi-fluorescence microscope for imaging of 
single cells in our previous studies [37, 38, 73, 75, 89, 90], In this study, the 
fluorescence filter cube (Chroma Tech) containing a band-pass excitation filter 
(455 ± 30 nm), band-pass emission filter (525±30 nm) and a dichroic mirror (500 
nm), was used for fluorescence imaging of expression of BmrA-EGFP.
Fluorescence spectroscopic study of accumulation kinetics of dyes in live 
cells
Fluorescence intensity of Hoechst 33342 (2 pM) incubated with the cells 
(OD6oo nm = 0.1) in the PBS buffer, in the presence or absence of glucose (25 
mM), and in the presence or absence of a pump inhibitor (25 pM orthovanadate) 
were acquired over time with 3 s time interval at room temperature using a 
fluorescence spectrometer (Perkin-Elmer, LS50B). The excitation and emission 
wavelengths were selected at 350 and 450 nm, respectively.
Structural modeling of fusion BmrA-EGFP transporters
The BmrA model was assembled using SWISS-MODEL, based upon 
existing homologous structural models of the ‘closed’ multidrug ABC transporter
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Sav1866 and LmrA with up to 33.7% sequence identity (PDB-codes: 2onj, 2hyd, 
1mv5) [84, 85]. The N- (24 amino acids) and C- (15 amino acids) terminal 
regions of this model were truncated, based on residues 269-829 of the template 
model Sav1866 (2hyd). The total energy of the complete model was reported as - 
16525.7 kJ/mol.
The EGFP model was assembled separately using SWISS-MODEL, 
based on 3D structure of the GFP (PDB-code: 3ogo) with a sequence identity of 
98.7%. The structure was truncated by 7 amino acids at the N-terminal and 3 
amino acids at the C-terminal.
To predict the secondary structures of the truncated regions connecting 
the EGFP domain to BmrA, the complete protein sequences of the fusion 
proteins were analyzed using the PSIPRED server [86]. The results (Fig. 11A-B) 
predicted the linker regions to be unstructured and thus conformationally flexible. 
The flexible linker regions were built manually and docked to the homology 
model termini using program Coot [91]. The EGFP domains were positioned as 
such that they were situated in the cytoplasmic space with no clashes to the ABC 
transporter. The final models (Fig. 11C-D) were visualized using PyMOL [92].
Note: All experiments in this dissertation were conducted in compliance 
with the university safety guidelines. The IBC approval number for recombinant 
DNA research in chapter II & IV is 12-008.
CHAPTER III
PROBING OF MULTIDRUG ABC MEMBRANE TRANSPORTERS OF 
SINGLE LIVING CELLS USING SINGLE PLASMONIC NANOPARTICLE
OPTICAL PROBES
INTRODUCTION
ATP-binding cassette (ABC) membrane transporters (efflux pumps) have 
been found in all living organisms, including bacteria and humans [52, 53]. For 
example, 78 ABC transporters have been reported in B. subtilis, and 48 ABC 
transporters have been identified in humans [52, 53, 55, 56]. Some of these 
transporters are involved in transport of a wide variety of structurally and 
functionally unrelated substrates (e.g., sugars, lipids, amino-acids, proteins, or 
xenobiotics), including extrusion of antibiotics or chemotherapeutic agents out of 
cells (e.g., bacteria or tumor cells). For example, P-glycoprotein accounts for 
multidrug resistance (MDR) in cancer cells, leading to ineffective treatments. 
Dysfunction of some of these ABC transporters causes severe diseases [9-11]. 
Despite extensive studies, such important and fascinating multi-substrate 
extrusion machinery and translocation mechanisms remain not yet fully 
understood [9, 52, 53].
Interestingly, all ABC transporters in any living organism share a common 
organization, possessing four core domains: two transmembrane domains (TMD) 
and two nucleotide-binding domains (NBD) [46, 59, 61, 93], The TMDs display 
quite variable sequence and topology, defining the substrate binding-sites and
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forming the transport passage-way for substrates to cross the membranes, while 
the NBDs have conserved sequences, empowering the transporters by binding 
and hydrolyzing ATP [46, 57, 61, 62], The similar structures and organization of 
ABC transporters suggest possible similar transport mechanisms.
B. subtilis (a Gram-positive bacterium) is a well-studied bacterium with a 
full-sequenced genome, and it is amenable to genetic manipulation [80], 
Therefore, B. subtilis has been widely used as a model organism for probing the 
function of prokaryotes and for better understanding of bacterial pathogenic 
functions (e.g., sporulation) and efflux function of multidrug membrane 
transporters, even though B. subtilis itself is not considered as a human 
pathogen [94, 95].
Currently, radioactively labeled substrates (14C and 3H) and the 
fluorescence dyes (e.g., rhodamine 123, Fluo-3, Hoechst dyes) are common 
probes for investigating efflux kinetics of multidrug transporters in bacterial and 
mammal cells [68, 69, 74, 76]. Fluorescence dyes, such as Hoechst dyes and 
ethidium bromide (EtBr), are quinolones, common substrates for multidrug 
membrane transporters in bacteria. The fluorescence dyes emit weak 
fluorescence in aqueous solution (outside cells) and become strongly fluorescent 
in non-polar and hydrophobic environments, especially as the dye molecules 
enter cells and intercalate with DNA [77]. Therefore, the time-dependent (time- 
course) fluorescence intensity of fluorescence dyes has been widely used to 
characterize efflux function of multidrug membrane transporters in bacterial and 
mammal cells [68, 69, 74, 76],
Although these conventional methods effectively provide ensemble 
accumulation kinetics of bulk cells, they are unable to determine transformation 
of pore sizes of ABC membrane transporters in response to various sizes of 
substrates in single living cells. Therefore, it is impossible to use them for probing 
size-dependent efflux kinetics of multidrug (multi-substrate) ABC membrane 
transporters for better understanding of their functions and molecular 
mechanisms. These limitations demand the development of new methods for 
probing the size-transformation of individual membrane transporters in single 
living cells in real time, in order to better understand molecular mechanisms of 
multidrug membrane transporters. Individual membrane transporters are likely to 
have unsynchronized membrane transport kinetics, underscoring the importance 
of probing the transport kinetics of single membrane transporters in single living 
cells in real time.
Currently, the sizes of membrane transporters are characterized at atomic 
resolution using X-ray crystallography or cryo-TEM [61, 93, 96]. However, neither 
methods can measure real-time transport dynamics of substrates and self- 
assembly of pump proteins in living cells. Therefore, the mechanisms and 
functions of membrane transporters remain elusive, even through structures of 
some membrane transporters at atomic resolution are now available [61, 93, 96].
Noble metal (e.g., Ag) nanoparticles (NPs) exhibit size-dependent optical 
properties, enabling us to image and determine the sizes of single NPs at 
nanometer (nm) scale in real time using dark-field optical microscopy and 
spectroscopy (DFOMS) [42-44, 73, 75, 90]. Notably, the size-dependent
localized surface plasmon resonance (LSPR) spectra (colors) of single NPs 
enable us to image the sizes of NPs in solution, single living cells and embryos at 
nm resolution in real time [39, 43, 44, 75, 89, 90, 97, 98]. These unique features 
allow us to use the color (LSPR spectra) index of the multicolor NPs as a 
nanometer-size index to directly measure sizes of single NPs as they are 
transported in and out of single living cells, and thereby to determine the sizes of 
membrane pores at the nm resolution in real-time [75, 89, 90]. Unlike fluorescent 
probes and semiconductor quantum dots (QDs), these noble metal NPs resist 
photodecomposition and blinking and show superior photostability [43, 44, 97], 
enabling them to serve as optical sized probes for tracking the transformation of 
pore sizes of membrane transporters and the size-dependent transport kinetics 
of efflux pumps for any desired period of time.
We have previously used the intrinsic optical properties of the noble metal 
NPs (e.g., Ag) for probing of sizes and transport dynamics of a single membrane 
transporter (MexA,B-OprM) in single living cells (P. aeruginosa, Gram-negative 
bacterium), and the transformation of pore sizes of their cellular membranes 
induced by antibiotics (e.g., aztreonam, chloramphenicol) at sub-100 nm spatial 
resolution and millisecond temporal resolution [75, 89, 90],
In this study, we synthesized and characterized stable and purified 
spherical Ag NPs with an average diameter of 11.8 ± 2.6 nm (8.4-31.5 nm). We 
used their sized-dependent LSPR spectra to determine the sizes of single NPs at 
nm resolution in real time, when they were in and out of single living cells, which 
enabled us to probe size-dependent efflux kinetics of BmrA (one of ABC
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membrane transporters) of single living bacterial cells (B. subtilis, Gram-positive 
bacterium). We also used the Ag NP probes to characterize BmrA fused with 
EGFP via its C- or N- terminus (Ct-BrmA-EGFP, or Nt-BmrA-EGFP) and to 
compare them with BmrA, aiming to determine whether the fused BmrA-EGFP 
maintains the efflux function of BmrA. We need to first determine whether BmrA- 
EGFP maintains the original efflux functions of BmrA, before we can use fused 
EGFP to visualize the BmrA locations and to characterize BmrA topologies, as 
those reported for other ABC transporters [65-67, 81].
RESULTS AND DISCUSSION
Synthesis and characterization of single Ag NP optical probes
We have synthesized spherical shaped Ag NPs and purified them by 
washing the NPs with nanopure deionized (Dl) water using centrifugation. This 
approach enables us to remove any residual chemicals from the synthesis and to 
produce highly purified NPs. We found that the purified Ag NPs were stable in Dl 
water for months, as we reported previously [44] . In order to maintain the 
viability of bacterial cells (B. subtilis), the cells must be suspended and incubated 
in the cell culture media or PBS buffer (0.5 mM phosphate buffered saline, 1.5 
mM NaCI). Notably, the studies of accumulation and efflux kinetics of multidrug 
membrane transporters (efflux pumps) in bacterial cells (Gram-negative or Gram- 
positive bacteria) using fluorescence molecules have been carried out in the 
buffer solution (PBS buffer), but not in the cell culture medium [54, 68, 71-73, 99].
Given concentrations and stages of the cells (e.g., O D 6oonm  = 0.1) must be 
incubated with given concentrations of fluorescence molecules (substrates), in 
order to determine the dependence of accumulation and efflux kinetics of 
membrane transporters on substrate concentrations and on the expression level 
of membrane transporters in given cells. Note that the cells grow and divide in 
the medium, leading to the change of cell concentrations and thereby impossible 
comparison of the results among the experiments. Therefore, the cells are 
typically harvested from cell culture media, well rinsed and dispersed in the PBS 
buffer with given concentrations (e.g., O D 6oo nm = 0.1) for probing of transport 
kinetics of membrane transporters in living cells [54, 68, 71-73, 99].
It is crucial to ensure that single Ag NPs are stable (non-aggregated) in 
the PBS buffer over time, in order to utilize the size-dependent LSPR spectra 
(colors) of single NPs to determine their sizes, to probe the pore sizes of 
membrane transporters and to study size-dependent and concentration- 
dependent efflux kinetics of single membrane transporters of single living cells in 
the buffer.
We characterized the sizes, shapes and LSPR spectra of purified Ag NPs 
in the buffer for 24 h at single-NP resolution using high-resolution transmission 
electron microscopy (HRTEM) and dark-field optical microscopy and 
spectroscopy (DFOMS), respectively. This approach enabled us to study the 
stability (non-aggregation) of purified Ag NPs in the buffer for 24 h at single-NP 
resolution. The results in Fig. 12A and B show single spherical NPs with an 
average diameter of 12.1 ± 4.8 nm, ranging from 8.4 to 31.5 nm. The
45
representative optical images of single NPs in Fig. 12C show that the majority of 
NPs are plasmonic blue NPs with some being green and few red NPs. 
Histograms of color (size) distribution of single NPs (Fig. 12D) from 20 images 
similar to that in Fig. 12C, show 74% blue, 22% green and 4% red NPs (Fig. 
12D-a), and 71% blue, 24% green and 5% red NPs (Fig 12D-b), before and after 
the NPs were dispersed in the buffer for 24 h, respectively.
We correlated the size distribution of single NPs measured by HRTEM 
(Fig. 12B) with the color (peak-wavelength of LSPR spectra) distribution of single 
NPs characterized using DFOMS (Fig. 12D), and found that blue, green and red 
NPs were correlated with NPs with diameters of 5-14 nm, 14-20 nm, and 20-32 
nm, respectively [39, 75]. Therefore, we used the LSPR spectra (colors) of single 
NPs to determine their sizes in real-time, and used them as sized-probes to 
characterize the transformation of pore sizes of membrane transporters in single 
living cells and to study the size-dependent transport kinetics of multidrug 
membrane transporters (BmrA) of single living cells.
We also characterized the sizes, optical properties and stability (non­
aggregation) of bulk Ag NPs in the buffer for 24 h using UV-visible absorption 
spectroscopy and dynamic light scattering (DLS). The UV-visible absorption 
spectra of purified Ag NPs before and after their incubation in the buffer for 24 h 
show an unchanged peak absorbance of 1.047 at 392 nm (Fig. 12E). The size 
distributions of the Ag NPs before and after their incubation in the buffer for 24 h
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Fig. 12 Characterization of sizes, shapes and plasmonic optical properties 
of single Ag NPs, and their stability (non-aggregation) in PBS buffer.
NPs dispersed in the PBS buffer for (a) 0 min and (b) 24 h. (A) Representative 
HRTEM image and (B) histogram of the size distribution of Ag NPs. (C) 
Representative dark-field optical image of single NPs and (D) histograms of color 
distribution of single NPs. (E) UV-visible absorption spectra of 1.4 nM Ag NPs 
show peak absorbance of (a) 1.047 at 392 nm and (b) 1.043 at 392 nm. (F) 
Histograms of size distribution of single NPs in solution measured using DLS 
show the average diameters of NPs at (a) 11.8 ± 2.6 nm and (b) 11.8 ± 2.8 nm. 
The scale bars are 10 nm in (A) and 10 pm in (C)
characterized using DLS show the same distribution range with the average 
diameters of NPs at 11.8 ± 2.6 nm and 11.8 ± 2.8 nm (Fig. 12F), respectively. 
The results indicate that the sizes of Ag NPs in the buffer remain unchanged for 
24 h. Interestingly, unlike our previous observations [44], the diameters of NPs 
measured in solution by DLS were slightly smaller than those measured under 
vacuum using HRTEM, which may be attributed to the negligible portion of larger 
NPs (18-30 nm in diameter) for ensemble measurements of DLS. In this study, 
the NPs in the buffer solution were used to characterize the efflux function of the 
BmrA transporter in single living bacterial cells (B. subtilis). Therefore, the 
average diameter of NPs is the one (11.8 ± 2.6 nm) measured in solution using 
DLS. Taken together, the results in Fig. 12 show that purified Ag NPs are stable 
in the buffer solution for 24 h.
Real-time probing of size-dependent efflux kinetics of BmrA using single 
Ag NPs
We used the size-dependent LSPR spectra (plasmonic properties) of 
single Ag NPs to probe the size-dependent efflux function of BmrA by incubating 
the Ag NPs with the living cells ( O D 6oonm  = 0.1) and tracking single NPs in and 
out of single living cells in real time.
The representative optical images of the cells with single intracellular and 
extracellular NPs in Fig. 13A and B show cross-sections of single rod-like 
bacterial cells. The size of single bacterial cells is about 2 pm in length and 0.5 
pm in width while the thickness of its cellular membrane is about 9 nm. Notably,
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the top and bottom membranes of single living cells are invisible under dark-field 
illumination, which demonstrates that the focal plane (depth of field at 190 nm) of 
dark-field microscope indeed allows us to image the thin-layer sections of single 
living bacterial cells and to visualize single NPs on the thin-layer section of single 
cells.
The dark-field microscope illumination needs to pass through the cellulaV 
membrane in order to irradiate intracellular NPs, and light scattering of 
intracellular NPs requires passage through the membrane in order to be imaged 
by the detector. The cellular membrane absorbs photons, leading to lower 
scattering intensity of intracellular NPs (dimmer). In contrast, the scattering 
intensity of the extracellular NPs on the membrane contains the scattering 
intensity of NPs and cellular membrane, leading to radiating imaging and higher 
scattering intensity. These features allow us to distinguish between the 
intracellular and extracellular NPs. The intracellular NPs are dimmer and more 
blurry than NPs in solution, as shown in Fig. 13A-a and B-a. In contrast, the 
extracellular NPs are radiating and much brighter than NPs in solution, as shown 
in Fig. 13A-b and B-b. Notably, we have validated these imaging approaches for 
determining intracellular and extracellular NPs by imaging ultra-thin sections of 
cells using TEM [75].
The representative LSPR spectra of single NPs in Fig. 13C show their 
peak wavelength (Amax) at 481 (blue), 535 (green) and 649 nm (red) NPs. Using 
the LSPR spectra (colors) of single Ag NPs, we identified the Ag NPs over any 
other possible cellular debris and vesicles, which do not have plasmonic
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properties and thereby appear white under dark-field illumination. Furthermore, 
size-dependent plasmonic spectra enable us to determine the sizes of single 
NPs in real-time using DFOMS via the calibration curves of the peak wavelength 
(Am ax) of LSPR spectra of single NPs versus their sizes, as we reported 
previously [39, 44, 75, 89, 90]. The sizes of single blue, green and red NPs in 
Fig. 13C are 13.3, 21.8, and 31.5 nm, respectively.
We incubated WT BmrA cells (ODeoonm = 0.1) with 1.4 nM Ag NPs and 
continuously imaged single NPs in and out of single living cells in real time. 
Snap shots from real-time videos in Fig. 14A and B show representative single 
blue and green NPs in and out of single living cells, respectively. The plots of 
single NPs in and out of singe living cells over time (Fig. 14C) show that the blue 
NP stays inside the cell for 66 min, while the green NP stays inside the cell for 14 
min. The LSPR spectra of the blue and green NPs, similar to the one in Fig. 13C, 
show the peak wavelength (A m ax)  at 479 nm and 540 nm, respectively. We 
determined the sizes of single blue and green NPs as 13.0 and 22.6 nm, 
respectively, using the correlation of sizes of single NPs determined by HRTEM 
with the peak wavelength of LSPR spectra (colors) of single NPs measured using 
DFOMS, as we reported previously [39, 75]. The results show that the smaller 
NPs stay inside the cell longer than larger NPs, suggesting size-dependent efflux 
kinetics of BmrA and indicating that smaller NPs are more biocompatible with the 
cells and they may be more suitable carriers for drug delivery.
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Fig. 13 Imaging of single intracellular and extracellular Ag NPs for single 
living bacterial cells using DFOMS.
(A) The representative optical image of the cells (BmrA, OD6oo nm = 0.1) 
incubated with 1.4 nM Ag NPs shows: (a) intracellular and (b) extracellular NPs, 
in dotted rectangles. (B) Zoom-in images of single cells illustrate (a) intracellular 
and (b) extracellular NPs. (C) LSPR spectra of single Ag NPs show peak 
wavelengths of representative blue, green, and red NPs at 481, 535, and 649 nm, 
respectively. The scale bars in (A) and (B) are 10 and 2 pm, respectively
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Taken together, plasmonic Ag NPs offer the feasibility for probing of size- 
dependent efflux kinetics of membrane transporters in single living cells in real 
time. Unlike fluorescence probes (e.g., Hoechst dyes), single Ag NPs possess 
size-dependent LSPR spectra and they are photostable (non­
photodecomposition and non-blinking) [43, 44, 97], These superior properties 
enable us to determine the sizes of single NPs in and out of single living cells in 
real-time, and use them to mimic various sizes of antibiotics (drugs) for probing 
efflux functions of multidrug membrane transporters.
Probing of dependence of accumulation rates of NPs on expression level of 
BmrA
To determine whether BmrA and BrmA-EGFP are responsible for 
extrusion of NPs out of living cells, we studied the dependence of accumulation 
kinetics of intracellular NPs upon the expression level of BmrA and BmrA-EGFP 
in bulk living cells at single living cell resolution. The results in Fig. 15A show that 
ABmrA (strain of deleted BmrA) cells accumulate the highest amount of the 
intracellular NPs over time and have the highest accumulation rate (slope of the 
plot) of intracellular NPs, while the Nt-BmrA-EGFP cells (over expression level of 
BmrA with its N-terminal fusion with EGFP) accumulate the lowest amount of 
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Fig. 14 Real-time probing of BmrA membrane transporter of single living 
cells using single Ag NPs by DFOMS.
Snapshots of sequential images of (A) a single blue NP (13.0 nm in diameter) in 
and out of single living BmrA cells at (a) 18.0, (b) 32.0, (c) 47.0, (d) 60.0, (e) 
74.0, and (f) 83.0 min; and (B) a single green NP (22.6 nm in diameter) in and 
out of single live cells at (a) 30.0, (b) 33.0, (c) 35.0, (d) 38.0, (e) 41.0, and (f) 44.0 
min. (C) Plots of imaging of in and out of single NPs in (A and B) versus time 
show the duration of single blue and green NPs staying inside the cells: (a) 66.0 
and (b) 14.0 min, respectively











Fig. 15 Study of the dependence of accumulation and efflux kinetics of 
single Ag NPs and fluorescent dye (Hoechst 33342) molecules on the 
expression level of BmrA.
(A) Plots of number of intracellular Ag NPs versus time and (B) plot of 
fluorescence intensity versus time for: (a) ABmrA, (b) Ct-BmrA-EGFP, (c) WT- 
BmrA, and (d) Nt-BmrA-EGFP cells, show that accumulation kinetics of 
intracellular NPs and fluorescence dye molecules in single living cells depend on 
cellular expression level of BmrA. In (A), the points with error bars represent the 
averages of experimental measurements with their standard deviations; the lines 
are added to guide the trend. At each point (every 20 min), 900 cells were 
analyzed
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Interestingly, the accumulation rate and amount of intracellular NPs in Nt- 
BmrA-EGFP cells are slightly lower than the WT (normal expression level of 
BmrA), while the accumulation rate in WT cells is slightly lower than Ct-BmrA- 
EGFP cells (over expression level of BmrA with its C-terminal fusion with EGFP). 
The results suggest that WT (BmrA), Nt-BmrA-EGFP and Ct-BmrA-EGFP cells 
extrude the intracellular NPs, leading to less accumulation of intracellular NPs 
than ABmrA cells. The results indicate that Nt-BmrA-EGFP and Ct-BmrA-EGFP 
maintain the efflux function of BmrA, and N-terminal fusion generates less steric 
effects on the efflux function of BmrA than C-terminal fusion.
The sizes of NPs are about ten times larger than conventional antibiotics. 
To determine whether the NPs are suitable substrates to mimic various sizes of 
antibiotics for probing the efflux functions of BmrA, we used a fluorescence probe 
(Hoechst 33342) to study the dependence of accumulation kinetics on the 
cellular expression level of BmrA for probing the efflux function of BmrA and 
BmrA-EGFP membrane transporters [54, 76]. The Hoechst dye is a well-known 
substrate of BmrA (ABC) membrane transporter and has been widely used for 
probing the accumulation and efflux function of BmrA. The Hoechst dye emits 
weak fluorescence in aqueous solution (outside the cells), and its fluorescence 
intensity increases substantially (up to 10-fold) as the dye molecules enter the 
cells and intercalate with DNA [77]. Therefore, one can use the fluorescence 
intensity of the Hoechst dye to monitor intracellular accumulation of dye 
molecules [54, 76]. By probing the dependence of the accumulated amount of
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the intracellular dye molecules on the expression level of BmrA membrane 
transporters, we determined the efflux kinetics of BmrA and BmrA-EGFP.
The results in Fig. 15B show that ABmrA cells accumulate the largest 
amount of intracellular dye molecules with the highest rate of accumulation 
(slope of the curve), whereas Nt-BmrA-EGFP cells accumulate the lowest 
amount of intracellular dye molecules with the lowest rate of accumulation. 
Notably, Nt-BmrA-EGFP cells, which have slightly lower accumulation rate and 
lower amount of the intracellular dye molecules than the WT cells, which have 
slightly lower ones than Ct-BmrA-EGFP cells. The results suggest that WT 
(BmrA), Nt-BmrA-EGFP and Ct-BmrA-EGFP extrude the dye molecules and 
thereby they accumulate less amount of the intracellular dye molecules than 
ABmrA cells, demonstrating that N-terminal or C-terminal BmrA fusion with 
EGFP maintains the efflux function of BmrA, and N-terminal fusion has less 
effect on the efflux function of BmrA than C-terminal fusion. Therefore, Nt-BmrA- 
EGFP and Ct-BmrA-EGFP cells become two new strains of BmrA available for 
further characterization of locations, structures and functions of BmrA. The 
results in Fig. 15B are similar to those observed using single NP optical probes 
(Fig. 15A), suggesting that single NP optical probes are well suited substrates for 
probing the efflux function of multidrug membrane transporters.
Unlike fluorescence probes, Ag NPs offer size information about the 
membrane permeability and substrates of the membrane transporters. The NPs, 
with sizes ranging from 8.4-31.5 nm, can enter the cells and be extruded out of 
the cells by BmrA and BmrA-EGFP transporters. Specifically, endocytosis,
56
pinocytosis and exocytosis, which are widely reported in eukaryotes, do not exist 
in prokaryotes (bacterial cells). Therefore, these processes are not responsible 
for the transport of NPs in and out of the bacterial cells (S. subtillis).
Study of effect of pump inhibitor on accumulation rates of NPs in single 
living cells
To determine whether BmrA and BmrA-EGFP membrane transporters are 
specifically responsible for the efflux of NPs, we studied the accumulation 
kinetics of the NPs in BmrA (WT), ABmrA, Nt-BmrA-EGFP and Ct-BmrA-EGFP 
living cells in the presence of a pump (ATPase) inhibitor, orthovanadate [82, 83]. 
The results in Fig. 16A show the higher accumulation rate of the NPs in the cells 
(WT-BmrA) in the presence of orthovanadate (Fig. 16A-a) than in its absence 
(Fig. 16A-b). In contrast, no significant change of accumulation of NPs in ABmrA 
cells was observed in the presence of the inhibitor (Fig. 16B).
Similar to WT cells, higher accumulation of NPs in Ct-BmrA-EGFP and Nt- 
BmrA-EGFP cells was observed in the presence of the inhibitor than its absence 
(Fig. 16C and D, respectively). These results show that the inhibitor affects the 
efflux of NPs by Ct-BmrA-EGFP, Nt-BmrA-EGFP and WT-BmrA transporters, 
suggesting that BmrA and BmrA-EGFP membrane transporters are indeed 
responsible for the efflux of NPs out of the cells. These results demonstrate that 
the NPs are the substrates of BmrA, and they are suitable optical probes to study 
efflux function of BmrA membrane transporters in single living cells.
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Study of concentration-dependent accumulation rates of NPs in single 
living ceils
We also investigated the dependence of accumulation rates of NPs on 
their concentrations (doses), in order to determine molecular mechanisms of 
entry of NPs into single living cells, and to compare them with those observed for 
antibiotics. We used two concentrations of NPs (0.7 and 1.4 nM) and studied 
their accumulation rates in BmrA (WT), ABmrA, Ct-BmrA-EGFP, and Nt-BmrA- 
EGFP cells. The results in Fig. 17 show the dependence of the number of 
intracellular NPs on NP concentrations for all strains of cells and the number of 
intracellular NPs increases as the concentration of NPs increases, suggesting 
that passive diffusion may play a role in transport of extracellular NPs into the 
cells, similar to passive diffusion of antibiotics into the cells.
The lowest number of intracellular NPs and lowest accumulation rates are 
observed in Nt-BmrA-EGFP (Fig. 17D), while the highest number of intracellular 
NPs and highest accumulation rates are found in ABmrA (Fig. 17B). Notably, the 
number of intracellular NPs at the equilibrium time, and accumulation rates in 
BmrA (WT) and Ct-BmrA-EGFP cells are similar to those observed in Nt-BmrA- 
EGFP. The results suggest that ABmrA cells are unable to extrude the NPs out 
of the cells, because of the absence of BmrA transporter, which leads to the 
highest accumulation of intracellular NPs. In contrast, the over-expression of Nt- 
BmrA-EGFP transporter effectively extrudes the NPs out of the cells, leading to 
the lowest accumulation of intracellular NPs. BmrA (WT) and Ct- BmrA-EGFP 
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Fig. 16 Probing of inhibitory effects of an inhibitor on accumulation and 
efflux kinetics of single Ag NPs for single living cells.
Plots of intracellular Ag NPs versus time: (A) BmrA, (B) ABmrA, (C) Ct-BmrA- 
EGFP, and (D) Nt-BmrA-EGFP, (a) in the absence (empty triangles) and (b) 
presence (filled triangles) of the inhibitor (25 pM, orthovanadate). The points with 
error bars represent the averages of three experimental measurements with their 
standard deviations; the lines are added to guide the trend. At each point (every 
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Fig. 17 Study of concentration dependent accumulation and efflux kinetics 
of single Ag NPs for single living cells.
Plots of intracellular Ag NPs versus time: (A) BmrA, (B) ABmrA, (C) Ct-BmrA- 
EGFP, and (D) Nt-BmrA-EGFP cells, incubated with (a) 1.4 (filled triangles) and 
(b) 0.7 nM (empty triangles) Ag NPs. The points with error bars represent the 
averages of three experimental measurements with their standard deviations; the 
lines are added to guide the trend. At each point (every 20 min), 900 cells were 
analyzed
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accumulation of intracellular NPs than ABmrA cells. Therefore, the accumulation 
rates of intracellular NPs in BmrA (WT) and Ct-BmrA-EGFP cells are similar to 
those observed in Nt-BmrA-EGFP. As observed in Figs. 15A and 16, the results 
in Fig. 17 also show the dependence of accumulation rates of intracellular NPs 
on the expression level of BmrA.
We summarize quantitative accumulation rates and equilibrium times of 
accumulation of intracellular NPs in single living cells (Figs. 16 and 17) in Table 
2, which shows their dependence on the expression level of BmrA, 
concentrations of NPs, and presence of the inhibitor.
Characterization of viability of single cells
Studies have found that Ag NPs show dose-dependent inhibitory effects 
on bacterial and tumor cells [39, 100]. Therefore, it is crucial for us to 
characterize the viability of cells that had been incubated with Ag NPs for hours, 
ensuring that Ag NPs did not affect the function and viability of the cells, and we 
indeed studied the membrane transporters (BmrA, BmrA-EGFP) of single living 
cells.
The viability of cells (WT, BmrA-EGFP, ABmrA) incubated with NPs 
throughout the duration of the experiments was characterized using live/dead 
bacL/ght viability and counting assay. The assay determines the viability of cells 
by detecting both live and dead cells using SYT09 nucleic acid stain and 
propidium iodide, respectively. Observation of the green fluorescence (Amax = 520
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nm) of SYT09 in bacterial cells shows viable cells. In contrast, the display of red 
fluorescence (Amax = 610 nm) of propidium iodide in bacterial cells indicates the
Table 2 Summary of accumulation rates and equilibrium times of single 









WT ABmrA Ctb Ntc WT ABmrA Ctb Ntc
0.7 0 1.1 1.6 1.0 1.1 40 60 40 40
1.4 0 1.5 1.8 1.3 1.2 40 60 40 40
1.4 25 1.7 1.8 1.9 2.1 80 120 80 80
a Orthovanadate
b Ct-BmrA-EGFP: cells with the over-expression of C-terminus BmrA fused with 
EGFP
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Fig. 18 Characterization of the viability of single bacterial cells using 
live/dead bacLight viability and counting assay.
(A) Dark field optical image and (B) fluorescence image of single bacterial cells 
(WT BmrA), incubated with 1.4 nM Ag NPs over the duration of each experiment 
for 4 h, show that the cells with intracellular NPs (dotted rectangles) or without 
NPs emit the green fluorescence (A ma x =  520 nm) of SYT09, indicating viable 
cells, (c) Plots of percentage of viable cells at (a) 0 and (b) 4 h, for BmrA, ABmrA, 
Ct-BmrA-EGFP, and Nt-BmrA-EGFP cells, show that 99-100% of the cells are 
alive. A minimum of 900 cells for each strain were assayed at each given time. 
The scale bars in (A) and (B) are 10 pm
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dead cells. Representative optical images of the cells (WT-BmrA) incubated in 
the PBS buffer with 1.4 nM Ag NPs for 4 h (Fig. 18A), show the cells with and 
without NPs. Their fluorescence images in Fig. 18B illustrate the green 
fluorescence cells, showing that the cells with and without NPs are alive. Similar 
phenomena are observed for Ct-BmrA-EGFP, Nt-BmrA-EGFP, and ABmrA cells.
By counting the number of live and dead cells, we determined the 
percentage of the viable cells by dividing the number of live cells with the total 
number of the cells. Note that, for each measurement, we assayed at least 900 
cells for each strain. The plots of the percentage of viable cells at the beginning 
and end of experiments in Fig. 18C show that more than 99% of the cells for 
each strain (WT, Ct-BmrA-EGFP, Nt-BmrA-EGFP, and ABmrA) were alive and 
viability remained constant throughout the duration of the experiments, 
demonstrating that we indeed studied the membrane transporters of single living 
cells. The results show that the NPs at these selected concentrations (1.4 nM) 
are biocompatible to the cells, demonstrating that the NPs are well suited for 
probing of membrane transporters of single living cells in real time.
SUMMARY
In summary, we have prepared purified and stable (non-aggregation) Ag 
NPs (11.8 ± 2.6 nm). In the given doses (1.4 nM), they are biocompatible with 
the cells. We utilized the size-dependent LSPR spectra of single NPs to 
determine the sizes of single NPs in and out of single living cells (B. subtilis) at 
nanometer resolution in real time using DFOMS, and to probe size-dependent
efflux kinetics of single BmrA membrane transporters (Ct-BmrA-EGFP, Nt-BmrA- 
EGFP) in single living cells in real-time. The results show that Nt-BmrA-EGFP 
and Ct-BmrA-EGFP transporters maintain the efflux function of BmrA, offering 
two new strains for the future study of BmrA. We found that the smaller NPs 
resided longer inside the cells than larger NPs, suggesting the size-dependent 
efflux kinetics of BmrA and indicating that smaller NPs are more biocompatible 
with the cells. Furthermore, accumulation and efflux rates of NPs for single living 
cells are dependent on the expression level of BmrA, concentration of NPs, and 
a pump inhibitor (orthovanadate), similar to those observed using a well-known 
substrate (Hoechst dye) of BmrA transporter, suggesting that NPs are substrates 
of BmrA transporters and they enter the cells via passive diffusion. Taken 
together, this study demonstrates that single plasmonic Ag NP optical probes are 
superior to fluorescence probes for study of efflux kinetics of multidrug 
membrane transporters in single living cells. Single Ag NPs exhibit size- 
dependent LSPR spectra and photostability (non-blinking and non­
photodecomposition), offering the feasibility of using them to mimic various sizes 
of antibiotics (drugs) for probing the size-dependent efflux kinetics of membrane 
transporters of single living cells at nm resolution in real-time.
METHODS
Reagents and cell lines
Live/dead bacL/ght viability and counting assay and Hoechst 33342 were 
purchased from Invitrogen; all other reagents were purchased from Sigma-
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Aldrich, and used as received. For cell lines of Bacillus subtilis, WT (BmrA) were 
purchased from Bacillus Genome Stock Center (BGSC), while ABmrA 
(previously named AYvcC, a mutant strain that is void of the BmrA) were 
provided by J. M. Jault [54], The cell lines of Ct-BmrA-EGFP (54A, a mutant with 
over expression level of BmrA with its C-terminal fusion with EGFP) and Nt- 
BmrA-EGFP (29A, a mutant with over expression level of BmrA with its N- 
terminal fusion with EGFP) were constructed in our laboratory. The design and 
characterization of Nt-BmrA-EGFP and Ct-BmrA-EGFP will be fully described 
and reported in elsewhere.
Synthesis and characterization of Ag NP optical probes
Silver NPs were synthesized and washed as we described previously [44, 
97]. The purified Ag NPs were dispersed in the PBS buffer (0.5 mM phosphate 
buffer, 1.5 mM NaCI, pH = 7.0). We characterized the sizes, concentrations and 
number of single NPs in the buffer over time to determine the stability (non­
aggregation) of NPs in the buffer. The sizes of single NPs were determined using 
high-resolution transmission electron microscopy (HRTEM) (FEI Tecnai G2 F30 
FEG) and dynamic light scattering (DLS) (Nicomp 380ZLS particle sizing 
system). The concentrations of NPs were measured and calculated, as described 
previously [97, 101]. Plasmonic absorption and scattering properties of bulk NPs 
were characterized using UV-visible spectrometer (Hitachi).
The plasmonic images and LSPR spectra of single NPs were acquired 
using dark-field optical microscopy and spectroscopy (DFOMS) equipped with
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CCD camera (Micromax, Roper Scientific) and Multiple-spectra imaging system 
(Nuance, CRI) [39, 43], The design and construction of DFOMS have been fully 
described in our previous studies [37-39, 42, 43, 97, 98,]. The dark-field optical 
microscope was equipped with a dark-field condenser (Oil 1.43-1.20, Nikon) and 
a 100x objective (Nikon Plan fluor 100x oil, iris, SL. N.A. 0.5-1.3, W.D. 0.20 mm) 
with the depth of field (focus) of 190 nm.
Cell culture and preparation
We pre-cultured the cells in an Erlenmeyer flask (250 mL) containing 20 
mL of L-broth (LB) medium (1% tryptone peptone, 0.5% yeast extract, and 0.5% 
NaCI, pH = 7.2) in a shaker (Lab-line Orbit Envivon-Shaker) (150 rpm, 37 °C) for 
12 h. We then cultured the cells (WT and ABmrA) in the LB medium for another 8 
h, and cultured the Ct-BmrA-EGFP and Nt-BmrA-EGFP cells in the medium 
containing 1% xylose for another 8 h to ensure the full expression of the EGFP. 
We harvested the cultured cells using centrifugation (Beckman Model J2-21 
Centrifuge, JA-14 rotor, at 7500 rpm, 23 °C, 10 min), washed the cells with the 
PBS buffer three times, and finally re-suspended the cells in the buffer. The final 
concentration of the cells was adjusted to O D 6oonm  = 0.1, and used for the entire 
study.
Imaging of single NPs in single living cells and probing cellular viability
The cell suspension ( O D 6oonm = 0.1) containing 0.7 and 1.4 nM Ag NPs in 
the absence and presence of orthovanadate (25 pM) were prepared. The timer
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was started to record the incubation time as the NPs were added into the cell 
suspension.
We transferred the mixture (20 pL) into a freshly prepared microchamber 
and continuously imaged and acquired LSPR spectra of single NPs in and out of 
single living cells in real time for 3 h using DFOMS, which enabled us to 
determine the sizes and positions of single NPs simultaneously. The construction 
of microchamber for imaging of single bacterial cells over time was fully 
described in our previous studies [37-39, 42, 43, 97, 98]. We could achieve the 
temporal resolution up to 5 ms with sufficient high signal to noise ratios for 
continuously imaging the transport of single NPs in and out of single living cells. 
However, we found that the transport of single NPs in and out of single living 
cells (Bacillus subtillis) was not a rapid process and a temporal resolution of 
seconds to two minutes was sufficient to track their transport in real time. This 
approach enabled us to avoid generating huge sizes (> 200 GB) of single data 
files that would be unnecessary and hard to handle and analyze.
We also sampled the mixture (20 pL) into a freshly prepared 
microchamber every 20 min and imaged the cells on ten representative locations 
in the microchamber using DFOMS equipped with a CCD camera. This approach 
enabled us to image massive amount of cells (3000 cells) for each sample to 
gain sufficient statistics for probing the accumulation rates of bulk cells at single 
cell resolution. We determined intracellular NPs and plotted them versus time to 
measure the accumulation rates of single NPs in the cells over time 
(accumulation rate = slope of the plot).
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At the end of each experiment, the viability of the cells was characterized 
using live/dead BacLight bacterial viability and counting assay [102]. We imaged 
the cells using dark-field optical microscopy and epi-fluorescence microscopy, 
and counted the green fluorescence cells (peak wavelength of fluorescence 
spectra of SYT09, Amax = 520 nm) and red fluorescence cells (peak wavelength 
of fluorescence spectra of propidium iodide, Amax = 6 1 0  nm) as live and dead 
cells, respectively.
Fluorescence spectroscopy measurements
Time-dependent (time-course) fluorescence intensity of Hoechst 33342 (2 
pM) incubated with the cells ( O D 6oo nm = 0.1) was measured at a 3-s data 
acquisition interval in real-time using a fluorescence spectrometer (Perkin-Elmer 
LS50B). The excitation and emission wavelengths were 350 and 455 nm, 
respectively.
Data analysis and statistics
For characterization of sizes, shapes, and LSPR spectra of single NPs 
using HRTEM and DFOMS, a minimal of 100 Ag NPs were imaged for each 
measurement. Each measurement was repeated three times. Thus, 300 NPs 
were characterized for each solution.
We acquired ~30 cells in a single CCD image in real time simultaneously. 
Therefore, we studied the transport of single NPs in and out of ~3Q of single 
living cells for eacji measurement. We repeated the experiment three times and
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hence -90 cells were studied to determine the transport of single NPs in and out 
of single living cells in real time.
We also acquired ten representative images of each cell suspension 
incubated with 0.7 or 1.4 nM Ag NPs every 20 min for 3 h to study accumulation 
rates of intracellular NPs in single living cells in the presence or absence of the 
inhibitor (orthovanadate, 25 pM). Therefore, a minimal of -300 cells was imaged 
every 20 min, and 2700 cells were studied over 3 h for each measurement. Each 
experiment was repeated three times. Thus, 8100 cells were studied for each 
sample, which allowed us to gain sufficient statistics for probing accumulation 
rates and efflux kinetics of bulk cells at single cell resolution. We analyzed the 
number of intracellular NPs in 900 cells (300 cells for each measurement) at 
each 20 min, plotted them over time, and used the slope of the plots to determine 
the accumulation rates of intracellular NPs in the cells in the presence and 
absence of the pump inhibitor (orthovanadate, 25 pM). The equilibrium times of 
accumulation of NPs in the cells were determined at the times when the 
accumulation rates of intracellular NPs remained unchanged over time. The 
amount of accumulated intracellular NPs for each strain refers to the amount of 
intracellular NPs at the equilibrium time.
For the study of viability of single cells, a minimal of 300 cells incubated 
with 1.4 nM Ag NPs for 12 h was assayed for each measurement. Each 
measurement was repeated three times. Thus, 900 cells were assayed for each 
sample.
Note: The following guidelines from the University of Oklahoma Health
Sciences Center were always followed whenever we are working with 
nanoparticles involved in the research studies shown in chapter III & V 
(http://www.ouhsc.edu/ibc/documents/NanoparticlesGuidelines-doc).
1. Wear lab coats at all times.
2. Wear gloves when handling nanoparticles and gloves must covere the 
hand and the wrist.
3. Wear long arm sleeves where high levels of exposure to nanoparticles 
were anticipated.
4. Wear standard lab safety goggles.
5. Perform work in a chemical hood or biological safety hood.
a. Never conduct aerosol producing activities (such as sonication, 
vortexing, or centrifuging) on an open lab bench.
b. Do not perform activities that could possibly release 
nanoparticles (such as emptying and opening of tubes) on an 
open lab bench.
c. Hand solutions containing nanoparticles over disposable lab 
bench covers.
6. Provide hand washing facilities in all labs. Wash hand after handling 
nanoparticles.
7. Clean lab bench tops and other surfaces after each experiment using 




STUDY OF STRUCTURE AND EFFLUX FUNCTION OF EGFP FUSED 
MEXA.B-OPRM MEMBRANE TRANSPORTER IN PSEUDOMONAS
AERUGINOSA
INTRODUCTION
MDR (Multidrug resistance) associated efflux pumps have been identified 
in many organisms, ranging from bacteria to humans [2, 5, 8, 47], In bacteria, the 
genes encoding for efflux pumps are usually located on the chromosome or 
transmissible genetic elements like plasmids and it is well known that the efflux 
pumps in bacteria confer lower susceptibility to antibiotics, however this does not 
necessarily result in increased antibiotic resistance which may be contributed by 
other causes than existence of efflux pumps [7, 103]. To date, five classes of 
efflux pumps are found associated with multidrug resistance: the MF superfamily, 
the SMR family, the multidrug and toxic-compound extrusion (MATE) family, the 
ABC superfamily and the RND family. Those efflux pumps are different in the 
number of assembled components, transmembrane domains, the energy 
sources used by pumps as well as the types of substrates exported by pumps [2, 
3, 5, 8, 46]. Among these MDR transporters, only the ABC efflux transporters are 
primary transporters with the rest being secondary transporters utilizing sodium 
or proton gradient as the source of energy, whereas the MF superfamily 
dominates in gram-positive bacteria, the RND family only exists in gram-negative 
bacteria [2, 5, 8, 103]. Besides from exporting multiple antibiotics out of cells,
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those efflux pumps are found to play new roles recently such that some efflux 
pumps of the resistance-nodulation-cell division (RND) family have been 
identified to have a role in the survival and colonization of the bacteria inside the 
host. In addition, other efflux pumps are found to be capable of exporting natural 
substances produced by the host [104-106].
Efflux pumps of RND family (e.g., MexA,B-OprM) which are expressed by 
gram-negative bacteria and are found to be responsible for multidrug resistance 
in clinical therapies are tripartite systems including the following three 
components: a transporter protein (e.g., MexB), which is located on the inner 
membrane of the bacterium; an outer-membrane protein (e.g., OprM), which is 
located in the outer-membrane of the bacterium and a membrane fusion protein 
(e.g., MexA) which is located in the periplasmic space [4, 107], Taking the MexA, 
B-OprM efflux pump as an example, it is generally thought that the transporter 
protein MexB captures its substrates either from within the lipid bilayer of inner 
membrane or from cytoplasmic contents, then transports them to the extracellular 
medium through OprM which forms a channel in the outer membrane [108]. The 
cooperation between MexB and OprM is coordinated by the periplasmic 
membrane fusion protein MexA [15, 109-112]. Efflux through RND-family pumps 
is driven by the proton motive forces, an electrochemical gradient resulted from 
the motion of hydrogen ions. Besides, the outer-membrane protein OprM of P. 
aeruginosa is found to interact with several other RND family proteins [7, 111].
Despite extensive studies, the translocation mechanisms of those 
transporters remain elusive [109-111, 113, 114]. Many fundamental questions
regarding molecular mechanisms and interactions of multidrug efflux transporters 
remain unanswered. For instance, the individual integrated steps of the catalytic 
cycle, which are responsible for transporting substrates out of the membrane, are 
still at large though a lot of researches in delineating the efflux mechanisms have 
been done in the past [45, 115-117]. Notably, fusing membrane transporters with 
EGFP will offer the opportunity to visualize them and thus to investigate their 
interactions with substrates that lead to their extrusions. However, the fusion of 
multi-drug efflux transporters with EGFP may disrupt their original efflux 
functions. Therefore, it is crucial to first confirm that these fusion proteins still 
maintain the original efflux functions prior to utilizing them to probe molecular 
mechanisms of multidrug efflux pumps.
The past two decades have witnessed numerous uses of fluorescent 
protein (e.g., GFP or its variants) in the study of localization and expression of 
proteins in all kinds of organisms [23, 118-120]. For example, fusing promoter 
region with fluorescent proteins has been used to identify the multidrug efflux 
pump genes in Caenorhabditis elegans and to visualize the locations of MDR 
transporters in fission yeast [24, 64], Besides, GFP has also been used as a 
fluorescence probe to characterize the topologies of multidrug efflux transporters, 
because GFP only fluoresces within the cytoplasmic space (reducing 
environment), but not in the periplasm or plasma area [65]. Studies have shown 
that GFP fusion proteins may alter the function of proteins. Unfortunately, the 
lacking of the systematic studies on these areas is often the case [121].
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Functional studies of multidrug efflux pumps in bacterial and eukaryotic 
cells often rely on measuring of the accumulation of radioactively labeled 
substrates (14C and 3H) or the fluorescence dyes (e.g., rhodamine 123, Fluo-3, 
Hoechst dyes) [68, 70]. Fluorescent dyes, such as Hoechst dyes and ethidium 
bromide (EtBr), are particularly suitable for the study of the MDR mechanisms 
because of the big increase of fluorescence intensities when they are changed 
from aqueous solutions to non-polar and hydrophobic environments, especially 
when the dye molecules intercalate with DNA. Therefore, change of time- 
dependent fluorescence intensity of fluorescence dyes will reflect the real-time 
state of the accumulation of substrates in bacterial and eukaryotic cells [71, 99].
Efflux functions of multidrug efflux pumps have also been characterized by 
determining the minimal inhibitory concentrations (MICs) of antibiotics. These 
antibiotics are specific substrates of these transporters and different strains have 
demonstrated the different susceptibility towards them. For example, a wide 
range of antibiotics such as chloramphenicol (CP), tetracycline (TET), gentamicin 
(GM), aztreonam (AZT), rifampicin (RIF), ofloxacin (OFLX) and novobiocin (NOV) 
have been utilized to detect the efflux functions of MexA,B-OprM efflux pump 
and different P. aeruginosa strains showed different MICs of the selected 
antibiotics [13, 116].
In this study, we constructed the EGFP-mexB fusion gene and 
successfully expressed it in AMexB strain of Pseudomonas aeruginosa, thus 
generating a new strain of Pseudomonas aeruginosa (MexA-EGFP-MexB-OprM). 
To determine whether EGFP-MexB subunit can coordinate with other two pump
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components-MexA and OprM to form a complete efflux pump and retain its efflux 
functions, we characterized the real-time extrusion of fluorescence dye 
molecules (EtBr) by these strains in the presence or absence of a MDR pump 
inhibitor-CCCP using fluorescence spectroscopy. We also determined the 
minimal inhibitory concentrations (MICs) of selected antibiotics such as AZT and 
CP for these strains. To our knowledge, fusion of EGFP with MexB transporter in 
Pseudomonas aeruginosa has not yet been reported and a functional EGFP 
fusion strain can be used to study functions and structures of MexA,B-OprM 
transporter in single living cells.
RESULTS AND DISCUSSION
Construction and characterization of EGFP-mexB fusion gene and its 
expression
We designed and constructed the EGFP-mexB fusion gene by fusing 
EGFP gene to the N-terminal of mexB gene and transformed the plasmid 
containing fusion gene into the AMexB strain to create a new strain of 
Pseudomonas aeruginosa (MexA-EGFP-MexB-OprMJ. The fusion plasmid, 
pMMB67EH-EGFP-MexB (67PB), is constructed as shown in Fig. 19 with details 
as described in the experimental section. Briefly, the genomic DNA of 
Pseudomonas aeruginosa was used to amplify mexB gene by a set of primers 
(mexB P1 and mexB P2) while EGFP gene was amplified from pEGFP vector via 
another set of primers (egfp P1 and egfp P2). Amplified EGFP and mexB PCR 
products were then subject to a secondary round of PCR amplification by a set of
primers (egfp P1 and mexB P2). Then the PCR products of EGFP-mexB fusion 
gene and vector (pMMB67EH) were then digested using a pair of restriction 
endonuclease enzymes (Sa/l/H/ndlll). The digested PCR products (3,750 base 
pairs, bp, EGFP-mexB gene) were finally ligated with the digested and purified 
vector (8,800 bp), pMMB67EH. This approach enables us to insert EGFP-mexB 
fusion gene into the vector to create the fusion plasmid (pMMB67EH-EGFP- 
MexB, 67PB).
The amplified PCR products were characterized using routine agarose gel 
electrophoresis and DNA sequencing. The results in Fig. 20A show that amplified 
PCR products of mexB and EGFP are about 3,000 bp and 750 bp, respectively, 
which agree well with the number of base pairs of the mexB and EGFP genes. 
The fusion plasmid (pMMB67EH-EGFP-MexB, named as 67PB by us) in Fig. 19 
was characterized using DNA agarose gel electrophoresis and DNA primer 
walking sequencing. The fusion plasmid digested by Sa/l/H/ncflll (Fig. 20B) 
showed two products of about 8,000 bp and 4,000 bp, which comply with 
expected sizes of digested vector and EGFP-mexB fusion gene, respectively. 
The DNA sequencing results of the fusion gene show that the sequences of the 
mexB gene are identical with those reported previously [14, 15, 116, 122] and 
that the EGFP gene is in same open reading form (ORF) with mexB gene without 
any linking sequence between them.
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Fig. 19 Schematic illustrations of construction of EGFP-mexB fusion gene.
(A) The double and single stranded EGFP gene (step l-ll) was amplified from 
plasmid pEGFP by a set of primers (egfp P1 and P2) and a single primer (egfp 
P1), respectively. (B) The genomic DNA from wide type PA01 strain was used to 
amplify double or single stranded mexB gene via a pair of primers (mexB P1 and 
P2) and a single primer (mexB P2) (step l-ll), respectively. The amplified 
products were further mixed and amplified by egfp P1 and mexB P2 primers 
through asymmetrical PCR to get the fusion gene EGFP-mexB (A-B, step III). (C) 
The fusion gene and vector (pMMB67EH) were digested by restriction enzymes 
(Sa/l/H/ndlll). The digested fusion gene products were then ligated with the 
digested vector, generating the fusion plasmid, pMMB67EH-EGFP-MexB (IV)
78
L1 12 L3 L4
4500 bp
B L1 L2
3800 bp  8800 bp
3000 bp 6000
K 4000 ^ --------3800 bp
2500
2000 





Fig. 20 Characterization of EGFP-mexB fusion gene using agarose gel 
electrophoresis.
A-L1: DNA markers/ladders in base pair (bp); L2: EGFP-mexB fusion gene 
amplified using the mix of amplified EGFP and mexB gene products as a 
template and egfp P1 and mexB P2 as primers; L3: mexB gene amplified using 
the genomic DNA of P. aeruginosa strain (PA01) as a template and mexB P1 
and P2 as primers; L4: EGFP gene amplified using the plasmid (pEGFP) as a 
template and egfp P1 and P2 as primers. Arrows point to the PCR products of 
about 750, 3,000 and 3,800 bp, which agree well with the number of base pairs 
of EGFP, mexB and EGFP-mexB genes. B-L1: DNA markers in bp; L2: 
pMMB67EH-EGFP-MexB plasmids are digested by a pair of restriction 
endonuclease enzymes, Sal\/Hind\\\. Arrows point to the digested vector 
plasmids of about 8,800 bp and EGFP-mexB fusion gene of about 3,800 bp
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Then we transformed the fusion plasmid (pMMB67EH-EGFP-MexB, 
67PB) into the AMexB strain (the strain with deletion of the mexB gene) to create 
a new strain of Pseudomonas aeruginosa (MexA-EGFP-MexB-OprM), and 
characterized its expression in single living cells by measuring fluorescence of 
EGFP in single living cells using fluorescence microscopy and spectroscopy. The 
results in Fig. 21 show that nearly 100% of the MexA-EGFP-MexB-OprM cells 
emit green fluorescence, but none of the wild-type strain (PA01), the efflux pump 
overexpressed strain (NalB) and the pump deleted strain such as AMexB and 
AMexA,B-OprM emit green fluorescence, demonstrating that the fusion gene are 
successfully transformed and expressed in the AMexB cells.
Thus, the new strain enables characterization of locations, topologies and 
functions of MexB component of MexA, B-OprM efflux pump in living cells, as 
those reported for other MDR transporters [65]. However, In order to use them to 
study the functions and structures of MexB proteins, we have to determine first if 
EGFP-MexB plus MexA and OprM components can form a functional extrusion 
pump.
Probing of dependence of efflux kinetics of transporters on their 
expression and the presence of pump inhibitor in live cells
Except from its use to label DNA fragment in molecular biological 
experiments, EtBr is also a well-known substrate of MDR transporters (e.g., 
MexA,B-OprM) and has been widely used to monitor the accumulation and efflux 
kinetics of these transporters [70, 99, 123, 124], Notably, the EtBr dye molecules
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emit weak fluorescence in aqueous solution (outside the cells), and their 
fluorescence intensity increases substantially (up to 10-fold), as they permeate 
into the cells and intercalate with DNA. Therefore, change of the fluorescence 
intensity of the EtBr dye molecules has reflected the real-time accumulation and 
efflux kinetics of multidrug efflux pumps in living cells.
Fig. 21 Characterization of expression of EGFP-mexB fusion gene in P. 
aeruginosa.
(A) Dark-field optical images and (B) green fluorescence images of single living 
cells: (a) PA01; (b) NalB; (c) AMexA,B-OprM; (d) AMexB and (e) MexA-EGFP- 
MexB-OprM strains, respectively. Scale bar = 5 pm
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To determine whether EGFP-MexB protein expressed in the AMexB cells 
can form a functional efflux pump with other components as MexA and OprM, we 
first studied the efflux kinetics of the EtBr dyes by those different P. aeruginosa 
strains containing different expression level of MexA,B-OprM pump proteins in 
living cells in real time using the fluorescence spectroscopy.
We measured the time-dependent fluorescence intensity of the EtBr dye 
molecules (10 and 40 pM) incubated with living cells (AMexB, MexA-EGFP- 
MexB-OprM, PA01, NalB and AMexA,B-OprM; ODeoonm = 0.1) in PBS (pH=7.2) 
over time. The results in Fig. 22 show that, the fluorescence intensity of the dye 
molecules increases over time, indicating that the dye molecules enter the cells 
and intercalate with intracellular DNA. Notably, the accumulation rates highly 
depend upon the expression level of MexA,B-OprM pump proteins. The results in 
Fig. 22A and B all show that the highest accumulation rate of the intracellular dye 
molecules with the highest fluorescence intensity was found in AMexA,B-OprM 
cells (deletion of MexA,B-OprM), while the lowest accumulation rate was 
observed in NalB cells (MexA,B-OprM pump overexpressed strain), regardless of 
the concentration of EtBr dyes used. The MexA-EGFP-MexB-OprM fusion strain 
only shows a slightly lower accumulation rate of dye molecules than the AMexB 
strain (deletion of MexB), suggesting that fusion of MexB with EGFP fails to 
restore the efflux function of MexB antiporter fully. This could be due to steric 
hindrance effects of fusing EGFP with MexB gene. In addition, the accumulation 
rate of dye molecules in the PA01 strain (Normal expression of MexA,B-OprM) is 


















Fig. 22 Study of the dependence of efflux kinetics of the intracellular dye 
molecules on the expression of MexA,B-OprM transporter in live cells.
Time-dependent fluorescence intensity of different concentrations (A-10pM, B-40 
pM) of EtBr dye molecules incubated with cells ( O D 6oo nm = 0. 1 in PBS, pH 7.2) 
over time: (a) AMexA, B-OprM, (b) AMexB, (c) MexA-EGFP-MexB-OprM (d) 
PAOl and (e) NalB strains
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Interestingly, the WT PA01 strain shows a slightly lower accumulation rate 
than the AMexB or fusion strain (MexA-EGFP-MexB-OprM) does, especially in 
the presence of 10pM EtBr dyes and this leads us to question whether it is 
enough to probe the function of MexA,B-OprM efflux pump just by monitoring the 
accumulation rates of EtBr dye molecules. The results we observed in this study 
might be due to the interplay of OprM with other MDR pump components such as 
MexX, MexY to form another MDR transporter (MexX,Y-OprM). Besides, other 
MDR pumps like MexC,D-OprJ, MexE,F-OprN and MexH,l-OprD in 
Pseudomonas aeruginosa could also extrude EtBr dyes [5, 47],
In addition, we also studied the effects of a PMF (proton motive force) 
inhibitor, CCCP, on the accumulation of intracellular EtBr dye molecules. The 
results in Fig. 23 demonstrated that in the presence of 0.1 mM CCCP [125], all 
strains have increased accumulation of EtBr dye molecules inside cells. This 
indicated that CCCP can inhibit the efflux function of MexA,B-OprM pump. But, 
the inhibitory effects are not specifically on this pump since the accumulation of 
EtBr dyes in AMexA,B-OprM strain also increased in the presence of CCCP. This 
could be due to the inhibitory effects of CCCP on other MDR pumps using PMF 
as energy sources such as MexC,D-OprJ and MexE,F-OprN.
Minimum inhibitory concentrations (MICs) of antibiotics for different 
Pseudomonas aeruginosa strains
P. aeruginosa has been reported to have intrinsic antibiotic resistance 
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Fig. 23 Probing of inhibitory effects of a pump inhibitor (CCCP) on efflux 
function of M exA,B-O prM  and MexA-EGFP-MexB-OprM transporters in live 
cells.
Time-dependent fluorescence intensity of the dye molecules (EtBr; 15 pM), 
incubated with cells (OD6oo nm = 0.1 in PBS, pH 7.2): (A) AMexA,B-OprM, (B) 
AMexB, (C) MexA-EGFP-MexB-OprM, (D) PA01 and (E) NalB, in presence (a) 
and absence (b) of CCCP (0.1 mM)
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(TET), azthreonam (AZT), gentamicin (GM) [5, 17, 112, 126,127],
To further access the efflux function of the fusion strain (MexA-EGFP- 
MexB-OprM), we determined the MICs of two sensitive antibiotics (CP and AZT) 
for five mutant strains. The results in Table 3 indicate that the fusion strain 
partially restored the efflux function of MexA,B-OprM pump as is shown by the 
very small difference between the MICs of AZT and CP in the mutant lacking 
MexB (MIC of AZT- 0.2 pg/mL and MIC of CP- 4 pg/mL) and those in the EGFP 
fusion strain (MexA-EGFP-MexB-OprM; MIC of AZT- 0.5 pg/mL and MIC of CP- 
8 pg/mL). However, there is a substantial difference between the MICs of AZT 
and CP in the EGFP fusion strain and those in the PA01 or NalB strain. For 
instance, MICs of AZT and CP in the PA01 strain are 25 and 3.13 pg/mL, 
respectively, while those in the NalB strain are 100 and 15.7 pg/mL, respectively.
Table 3 MICs of CP and AZT in different Pseudomonas aeruginosa strains
Strains Properties MIC (pg/mL) Reference
CP AZT
_ r a  a i
PAO4290 PA01 (WT) 25 3.13 [13]
TNP082 NalB (Overexpression) 100 15.7
TNP071 AMexB 4 0.2
TNP076 AMexA.B-OprM 1.56 0.2
EGFP Fusion MexA-EGFP-MexB-OprM 8 0.5
Structural modeling of the MexA-EGFP-MexB-OprM multidrug efflux pump
Initial coordinates of the complete trimeric pump were obtained from the 
data-driven docking of AcrA-TolC onto AcrB [128], The individual components of
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the tripartite multidrug efflux pump from P. aeruginosa are highly homologous to 
the corresponding components in the MexA,B-OprM transporter system with up 
to 69 % sequence identity between the antiporter AcrB and MexB [84], Three 
dimensional structure alignment showed low average RMSDs for coordinate 
displacements of 2.053 A for AcrA/MexA (PDB codes: 2F1M and 1VF7), 2.355 A 
for AcrB/MexB (PDB codes: 2J8S and 2V50) and 2.064 A for TolC/OprM (PDB 
codes: 2VDD and 1WP1) [129, 130]. The working model was assembled by 
secondary structure matching of MexB on AcrB in its trimeric configuration [91, 
130]. The EGFP model was assembled separately using SWISS-MODEL [85], 
based on 3D structure of the GFP (PDB code: 30G 0) with a sequence identity of 
98.7%. Secondary structures prediction [86] showed the linker region connecting 
the C-terminus of the EGFP domain to the N-terminus of MexB to be 
unstructured. The connecting residues were built manually using program Coot 
[91]. The EGFP domains were positioned in the cytoplasmic space with no 
clashes to the MexB domains and the membrane region. All Figures (Fig. 24A-B) 
were generated using PyMOL [92].
Fig. 24A shows the assembled MexA-MexB-OprM model based on the 
coordinates of the data-driven docking model of the multidrug efflux pump AcrA- 
AcrB-TolC from P. aeruginosa [128]. The model shows the location of the MexB 
N-termini at the cytosolic end of the translocation pore of the transporter system 
with the unstructured loop of the N-termini pointing inward towards the trimeric 
pore.
Outer Membrane
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Fig. 24 Structural analysis of the assembled MexA-MexB-OprM and MexA- 
EGFP-MexB-OprM trimers.
(A) Bottom view of the assembled MexA-MexB-OprM trimer. The membrane
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fusion protein MexA and the outer membrane channel OprM are shown in 
turquoise and violet, respectively. The individual antiporter MexB monomers are 
depicted in red, orange and light brown. Black O rings point to the position of the 
N-termini of the MexB monomers at the end of the N-terminal loop pointing 
towards the translocation pore of the trimeric antiporter; (B) Side (a) and bottom 
(b) view of the proposed model of the MexA-EGFP-MexB-OprM trimer
Fig. 24B shows the EGFP domains fused to the N-terminal of MexB in its 
trimer assemblage. Spatial placement of the EGFP domains in the cytosol is 
limited by potential EGFP to EGFP, or EGFP to MexB clashes in the trimeric 
configuration (Fig. 24B). The position and orientation of the N-terminal fused 
EGFP domains may either partially block the translocation pore, or restrict the 
movement of the individual pump domains thereby restricting efflux activity.
SUMMARY
In summary, we have designed and constructed a EGFP-mexB gene and 
successfully expressed the fusion gene in the AMexB strain to generate a new 
strain of Pseudomonas aeruginosa (MexA-EGFP-MexB-OprM). We studied the 
dependence of accumulation kinetics of intracellular fluorescence molecules 
(EtBr, a pump substrate) on the expression level of MexA,B-OprM pump proteins 
for each of the strains (PA01, NalB, AMexB, MexA-EGFP-MexB-OprM and 
AMexA,B-OprM), by measuring the time-dependent fluorescence intensity of the 
intracellular dye molecules using fluorescence spectroscopy. We found that
MexA-EGFP-MexB-OprM can extrude the pump substrate (EtBr). However, there 
is no big difference in terms of the accumulation rate of intracellular fluorescent 
dyes between the fusion strain and the AMexB strain. Besides, CCCP was 
shown to inhibit the efflux pumps in all the tested strains. Also Minimum Inhibitory 
Concentration (MIC) studies of two selected antibiotics in these two strains 
yielded outcomes of only about two times of differences. These results all 
suggest that the fusion strain partially restores the efflux function of MexA,B- 
OprM transporter, even though we observed the positive interaction between 
EGFP part of fusion protein with Ag nanoparticle based bio-sensor during the in 
vitro experiment (Data not shown). Putative structural analysis shows a possible 
obstruction of the EGFP part to the MexB one, resulting in conformational 
hindrance, which may obstruct MexB to coordinate with MexA and OprM to form 
a completely functional efflux pump.
Work is in progress to create the new strains for probing molecular 
mechanisms and structures of the MexA,B-OprM multidrug resistance efflux 
pump. Future work can be done on the fusion of GFP variants (RFP and CFP) to 
other two subunits (MexA and OprM). The Fluorescence Resonance Engery 
Transfer (FRET) study between either of two or three subunits of MexA,B-OprM 
efflux pump can be performed as well to study the interplay between them. 
Those future studies combined with utilization of nanoparticle based optical 
sensors to probe the efflux functions of this MDR transporter will provide more 
insights into its molecular mechanisms. However, it remains a challenge to get 
three fully functional fusion proteins [113,114],
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METHODS
Reagents and cell strains
PCR polymerase (Agilent Technologies), plasmid isolation kit (Qiagen), 
DNA gel extraction kit (Qiagen), DNA ligation kit (Roche) which includes ligation 
enzyme (T4 DNA ligase) and ligation buffer, Sall/Hindlll (NEB), Tetracycline 
(Calbiochem), Chloramphenicol (Calbiochem), IPTG (GBT), CCCP (carbonyl 
cyanide-m-chlorophenylhydrazone, £ 97%, Sigma), Carbenedllin (Sigma), 
Aztreonam (Sigma), ethidium bromide (Invitrogen), and E. coli DH5a (Invitrogen) 
were purchased and used as received. P. aeruginosa strains (WT, NalB1, 
AMexB, AMexA,B-OprM) and plasmid (pMMB67EH) were provided by Hiroshi 
Yoneyama [131, 132]. All other reagents except indicated were purchased from 
Sigma and used as received. The nanopure deionized (Dl) water (18 MQ water, 
Barnstead) was used to prepare all solutions. The L-broth (LB) medium (1% 
tryptone, 0.5% yeast extract and 0.5% NaCI in Dl water, pH = 7.2) was prepared.
Design and construction of EGFP-mexB fusion gene
We fused N-terminal of mexB gene with C-terminal EGFP to prepare the 
EGFP-mexB fusion gene by asymmetrical PCR amplification, and then inserted it 
into the vector (pMMB67EH) to prepare pMMB67EH-EGFP-MexB vector [133]. 
We first used one pair of egfp primers (egfp primer-1: 5’-CTT GTC GAC AAG 
GGG ATC CAC CAT GGT GAG CAA GG-3’ and egfp primer-2: 5'-CAA TGA 
AAA ACT TCG ACA TCT TGT ACA GCT CGT CCA TGC-3’) and EGFP plasmid 
as a template to amply EGFP gene. We then used only egfp primer-1 and
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amplified double stranded EGFP gene as the template to create the coding 
strand of EGFP gene (ss-egfp). Using the similar approaches, we used one pair 
of mexB primers (mexB primer-1: 5’-GCA TGG ACG AGC TGT ACA AGA TGT 
CGA AGT TTT TCA TTG-3’, mexB primer-2: 5’-GAT AAG CTT ATC ATT GCC 
CCT TTT CGAC-3’) and genomic DNA of P. aeruginosa as the template to 
generate and amplify the mexB gene. We used mexB primer-2 and the amplified 
double stranded mexB genes as the template to generate and amply the 
template strand of mexB gene (ss-mexB), which has 20 bases that are 
complimentary to the ss-egfp at the 3’ ends. By mixing the ss-egfp with ss- 
mexB, it creates 20 bp double stranded DNA, that links the ss-egfp with ss- 
mexB, which is used as the template to generate and amply egfp-mexB fusion 
gene using both egfp primer-1 and mexB primer-2 as primers. The PCR 
products of the egfp-mexB fusion gene were characterized by agarose gel 
electrophoresis (0.8%, E = 8-10 V/cm), and purified by the gel purification kit 
(Qiagen).
The purified PCR products of EGFP-mexB genes and vector 
(pMMB67EH) were digested by a pair of restriction enzymes (Sa/l/H/ndlll), which 
was carried out by incubating the PCR products (10 ng) or the vector (5 ng) with 
two units of SalUHindlW each in the presence of 10x digestion buffer (4 or 3 pL) in 
Dl water (40 or 30 pL) at 37 °C for 3 h, respectively. The digested products were 
characterized by the agarose gel electrophoresis and purified via the gel 
extraction kit. After purification, the digested and purified EGFP-mexB genes 
were ligated into the same treated vector (pMMB67EH) to produce pMMB67EH-
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EGFP-MexB. The ligation was carried out by incubating digested and purified 
EGFP-mexB fusion genes (20 nM) with digested and purified vector (5 nM) in the 
presence of one unit of T4 DNA ligase and 10x ligation buffer (2 pL) in Dl water 
(20 pL) at 12 °C overnight. All digestion, gel electrophoresis and ligation work 
are carried out using standard protocols [134].
The pMMB67EH-EGFP-MexB was then transformed into DH5a competent 
cells (Invitrogen). Briefly, we mixed the pMMB67EH-EGFP-MexB (10 pL, 0.1 
pg/pL) with the competent cell suspension (100 pL, 2x107cells/mL), placed the 
mixture on ice for 30 min, followed by a heat shock at 42 °C for 90 s, then placed 
it back onto the ice for another 2 min. We then added the LB media (1 mL) to the 
mixture, incubated it in a shaker (LabLine Orbit-Environ, 37 °C, 200 rpm) for 1 h, 
and centrifuged the solution at 5000 rpm for 5 min. We removed the supernatant 
and suspended the pellets (transformed cells) in the fresh medium, spread them 
onto LB agar plates (0.5% yeast extract, 0.5% NaCI, 1% tryptone,1.5% agar and 
100 pg/ml ampicillin) and incubated the plates at 37 °C for 24 h. Positive 
ligations were verified by restriction enzyme digestion (Sal\/Hind\\\), PCR 
amplification with use of primers (egfp primer-1 and mexB primer-2), and DNA 
sequencing (Applied Biosystem, 3730x1 DNA Analyzer).
Plasmid with the correct sequence was finally transformed into MexB 
deleted strain (AMexB) using electroporation [135-138]. Briefly, the cells 
(AMexB) were cultured in the LB media under shaking at 37 °C until they reach 
the early log phase (OD6oo nm -  0.3-0.5). The cells were then harvested using
centrifugation (7000 g, 10 min, 4 °C), and washed with the sucrose (300 mM) 
three times, and resuspended in the sucrose. The cell suspension was placed 
on ice for 30 min before electroporation. We then mixed the competent AMexB 
cells (80 pL) with the fusion plasmid (pMMB67EH-EGFP-MexB, 10 pL, 1 pg/pL), 
transferred them to a pre-chilled sterile electroporation cuvette (gap between two 
electrodes = 0.2 cm), and applied the electric pulses (2.5 kV, 25 pF, 5 ms) 
(Biorad Gene Pulser). The cells were then cultured in the LB medium (3 mL) in 
the shaker (200 rpm, 37 °C) for 2 h, and harvested using centrifugation (5000 
rpm, 5 min). The cells were streaked onto the LB agar plate containing 100 
pg/ml carbenecillin, which was then incubated at 37 °C for 24 h. The clones 
were picked and cultured at 37 °C in the LB medium with 100 pg/mL carbenecillin 
to produce EGFP fused cells, MexA-EGFP-MexB-OprM.
Cell Culture and Assay
We pre-cultured each of five strains of P. aeruginosa: WT, NalB1, AMexB, 
AMexA,B-OprM, and MexA-EGFP-MexB-OprM, by inoculating a single clone of 
each strain from the LB agar plates into the LB medium and placed them in the 
shaker (37 °C, 200 rpm) for 12 h. We then cultured the cells in the fresh LB 
medium in the shaker (37 °C, 200 rpm) for another 8 h, except adding 2 mM 
IPTG and 100 pg/mL carbenecillin in the medium for the culture of MexA-EGFP- 
MexB-OprM cells to induce the expression of the fusion protein as the OD6oo nm 
(optical density, absorbance, at 600 nm) of the cell suspension reaches 0.5. We 
harvested the cells using centrifugation (Beckman J2-21, JA-14 rotor, 6000 rpm,
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23 °C , 10 min), washed them with the PBS buffer (50 mM phosphate, 100 mM 
NaCI, pH 7.0) three times, and resuspended them in the buffer. The cell 
concentration in the buffer (OD6oo nm = 0.1) was used to characterize the 
expression of the fusion protein (EGFP-MexB) in single live cells using 
fluorescence microscopy and to study the efflux function of membrane 
transporters by measuring accumulation kinetics of EtBr dyes in the cells using 
fluorescence spectroscopy.
Characterization of expression of fusion gene in single living cells using 
fluorescence microscopy
The cells suspended in the PBS buffer were imaged in a microchamber 
using dark-field optical microscopy and epi-fluorescence microscopy (Nikon, E- 
400) equipped with a CCD camera (Micromax, Roper Scientific) [71, 75, 90]. 
The design and construction of the microchamber and dark-field optical 
microscopy for imaging of single cells were fully described in our previous studies 
[71, 90]. In this study, the fluorescence filter cube (Chroma Tech) containing a 
band-pass excitation filter (455 ± 30 nm), band-pass emission filter (525 ± 30 nm) 
and a dichroic mirror (500 nm), was used for imaging expression of EGFP-MexB 
fusion protein in the strain (MexA-EGFP-MexB-OprM). The dark-field optical 
microscope is equipped with a dark-field condenser (Oil 1.43-1.20, Nikon) and a 
10Ox objective (Nikon Plan fluor 100xoil, iris, SL. N.A. 0.5-1.3, W.D. 0.20 mm).
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Fluorescence spectroscopic study of transport of EtBr dye molecules in 
living cells
Fluorescence intensity of EtBr (10 and 40 pM) incubated with the cells 
( O D 6o o n m =  0.1) in the PBS buffer in the presence or absence of 0.1 mM CCCP 
were acquired over time (1-2 h) with 3-s time interval at room temperature using 
a fluorescence spectrometer (Perkin-Elmer, LS50B). The excitation and emission 
wavelengths were selected at 465 and 600 nm with a width of each slit at 10 nm, 
respectively.
Minimum inhibitory concentration (MIC) studies for different Pseudomonas 
aeruginosa strains
We measured the MICs of two representative antibiotics (AZT and CP) 
toward the cells: WT, NalB1, AMexB, MexA-(EGFP-MexB)-OprM, and AMexA.B- 
OprM. Each strain was pre-cultured by inoculating a single clone from the LB 
agar plates into the LB medium (add 100 pg/mL carbenecillin for culturing the 
EGFP fusion strain to maintain the plasmid) and shaken overnight (200 rpm, 37 
°C). The cell suspension (100 pi, ~104 cells) was added into the fresh LB 
medium (2.9 mL) in the presence of a set of different concentrations of AZT or 
CP (add 100 pg/mL carbenecillin and 2 mM IPTG in the culture of the fusion 
strain to induce the expression of fusion protein), and shaken for another 16 h 
(200 rpm, 37 °C). The concentration and number of the cells for each cultured 




SIZE-DEPENDENT ANTIBACTERIAL EFFECTS OF SILVER 
NANOPARTICLES CONJUGATED ANTIBIOTICS ON GRAM-NEGATIVE 
BACTERIA, PSEUDOMONAS AERUGINOSA
INTRODUCITON
The development of nanotechnology presents us new therapeutic and 
diagnostic concepts in a wide variety of biological and medical processes. Due to 
their unique characteristics, nanoparticles are considered to have wide 
applications in biosensing [139], bioimaging [140] and targeted drug delivery 
[141]. For example, nanoparticles are used to enhance oral delivery by improving 
the solubility of poorly absorbed drugs [142]. They are capable of penetrating the 
cells to help cellular internalization and connective tissue permeation, thus 
delivering the drugs efficiently to the targeted tissue without clogging capillaries 
[143, 144], The basic requirements for targeted drug delivery are that the carrier 
should be circulated extensively in the bloodstream, it must be small enough to 
access target tissues and target cells, it has to be capable of delivering the 
loaded cargos into the cells, and following endocytosis, it must be able to escape 
endosome-lysosome processing. Different types of nanoparticles with 
biomedical relevance such as polymeric nanoparticles, dendrimers, liposomes, 
quantum dots, metal nanoparticles, etc. have been extensively studied in the 
past [145]. Of them, noble particles like Ag or Au NPs have been used to 
delivery protein-based drugs and are of particular utility because the unique
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optical, chemical and electronic properties of noble NPs made them well suited 
for biomedical sensing, therapeutic drug delivery [26, 44, 71, 90, 97, 145].
With significant developments in the understanding of nanosystems, 
research efforts are focused on integrating them with biology. Resistance of 
bacteria to bactericides and antibiotics has been a research subject of great 
interest due to the development of multidrug resistant strains [2, 9, 12, 17]. The 
resistance to bactericides or antibiotics is largely because of active efflux of 
antibiotics outside cells by multidrug resistance (MDR) transporters on the 
membranes [1-12, 45, 46, 56, 62, 146]. Numerous researchers have explored the 
feasibility and efficiency of using nanomaterials as new drug carriers. For 
instance, Gu et al. reported the enhanced antimicrobial effects of nanoparticles 
conjugated with vancomycin [147], Grace et al. used the gold nanoparticles 
conjugated with drugs and investigated their antimicrobial effects in various types 
of organisms [148]. Other researches also characterized the enhanced 
antibacterial effects of drug conjugated silver nanoparticles [149-151], All these 
research results demonstrated enhanced antibacterial effects of nanoparticles 
when conjugated with different drugs, which raises hopes in applying 
nanoparticles as effective drug carriers for the specific targeting and treatment of 
many MDR related diseases. While there were many reports about the delivery 
of different drugs in nanoparticle conjugated forms, little efforts were made, so 
far, to determine how the sizes of nanoparticle carriers would impact on the 
efficiency of antibiotic therapies.
Hence, in this study, we compared the therapeutic efficiency and 
biocompatibility of AgMUNH2-OFLX NPs with respect to their carrier sizes (2.4 ± 
0.7 nm, 13.0 ±3.1 nm and 92.6 ± 4.4 nm) and drug free forms (OFLX). Notably, 
we found the size-dependent antimicrobial effects of silver NPs conjugated 
antibiotics (OFLX) on gram-negative bacteria, P. aeruginosa, which were that 
larger sized NPs conjugated antibiotics generated higher inhibitory effects 
against the growth of bacteria than smaller sized NPs conjugated antibiotics at 
the same concentration of conjugated antibiotics and two of larger sized NPs 
conjugated antibiotics showed lower MIC values than their drug free forms. Thus 
our results offer new insights into design of more effective drug delivery vehicles 
and suggest that antibiotics conjugated with silver NPs might be used in therapy 
for better treatment of multidrug resistance associated diseases.
RESULTS AND DISCUSSION
Synthesis and characterization of different sized silver (Ag) nanoparticles
First, we have synthesized three sized Ag NPs (2.4 ± 0.7 nm, 13.0 ± 3.1 
nm and 92.6 ± 4.4 nm) according to the methods described in the experimental 
section. Next, we characterized these three sized Ag NPs using UV-visible 
spectroscopy (Fig. 25A) and the results demonstrated that 2.4 ± 0.7 nm silver 
NPs showed the peak of wavelength at 392 nm (Fig. 25A, I), while 13.0 ± 3.1 and
92.6 ± 4.4 nm Ag NPs showed the peak wavelengths at 398 nm (Fig. 25A, II) and 
482 nm (Fig. 25A, III), respectively. We also characterized their sizes using high 
resolution transmission electron microscopy (HRTEM) (Fig. 25B) and the
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corresponding histograms of size distribution of each sized Ag NPs (Fig. 25C) 
showed that the average diameters of three sized Ag NPs are 2.4 ± 0.7, 13.0 ± 
3.1 and 92.6 ± 4.4 nm, respectively. Taken together, those results are quite 
consistent with our previous studies [38, 42, 43],
Conjugation of ofloxacin (OFLX) to Ag NPs and characterization of Ag 
carriers by UV-visible spectroscopy
After synthesis of three sized Ag NPs, they were coated with MUNH2 
groups first before linking with the drug molecules (OFLX). After conjugation, 
OFLX conjugated NPs solutions were centrifuged and washed extensively to 
remove any unbound drug molecules. Successful conjugation was verified by the 
red shift in the UV-visible spectra before and after conjugation. As shown in Fig. 
26A-C, the UV-visible spectra of each sized Ag, AgMUNH2, AgMUNFh-OFLX 
NPs all showed a red-shift of peak wavelength as Ag NPs (Fig. 26A-C, a) are 
conjugated with MUNH2 groups first (Fig. 26A-C, b). Then, there were another 
red-shift of peak wavelength and the emergence of the peak wavelength of OFLX 
at around 325 nm as each sized AgMUNH2 NPs were finally linked with OFLX 
molecules (Fig. 26A-C, c). All these results suggest that each sized Ag NPs are 
successfully conjugated with MUNH2 groups and OFLX drug molecules step by 
step. [For abbreviation, Ag, AgMUNH2, AgMUNH2-OFLX NPs of three sizes will 
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Fig. 25 Synthesis and characterization of different sized silver 
nanoparticles.
(A) UV-visible spectra of three sized Ag NPs. (B) Representative TEM images of 
three sized Ag NPs. Scale bars are shown in each image. (C) Histograms of size 
distribution of three sized Ag NPs from TEM images. (I) 2.4 ± 0.7 nm Ag NPs, 
(II) 13.0 ± 3.1 nm Ag NPs and (III) 92.6 ± 4.4 nm Ag NPs


















Fig. 26 Characterization of three sized Ag, AgMUNH2 and AgMUNH2-OFLX 
NPs by UV-visible spectroscopy.
UV-visible spectra of (A) 2.4 nm Ag carriers, (B) 13.0 nm Ag carriers, (C) 92.6 nm 
Ag carriers ; a- Ag NPs, b- AgMUNH2 NPs, c- AgMUNH2-OFLX NPs
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Characterization of Ag, AgMUNH2 and AgMUNH2-OFLX NPs by DFOMS and 
LSPR Spectroscopy
Aside from the characterization of Ag, AgMUNH2, AgMUNH2-OFLX NPs 
by UV-visible spectroscopy as shown above, we also characterized them using 
our Dark Field Optical Microscopy Spectroscopy (DFOMS) system [37, 38, 42- 
44, 98]. In addition, we measured the representative LSPR spectra of each sized 
Ag, AgMUNH2 and AgMUNH2-OFLX NPs using our Nuance multispectral 
imaging system (CRI).
Fig. 27 showed the representative dark field images and LSPR spectra of 
each sized Ag, Ag MUNH2 and AgMUNH2-OFLX NPs. As shown in Fig. 26, for 
each sized Ag carriers, the peak wavelengths of Ag carriers start to shift into red 
direction as Ag NPs are conjugated with MUNH2 groups and followed by another 
red shift when AgMUNH2 groups are linked with OFLX drug molecules. In 
consistence with the above UV-visible spectra results, we also found that the 
peak wavelengths of representative LSPR spectra of each sized Ag, AgMUNH2, 
AgMUNH2-OFLX NPs showed a stepwise red shift from Ag NPs to AgMUNH2 
NPs, and to AgMUNH2-OFLX NPs as depicted in Fig. 27, which showed 
representative dark-field images and LSPR spectra of 2.4 nm (A), 13.0 nm (B) 
and 92.6 nm (C) Ag carriers, respectively. The dark-field images of each type of 
Ag carriers are in the order of Ag (a), AgMUNH2 (b) and AgMUNH2-OFLX (c) 
NPs and the corresponding LSPR spectra of Ag carriers (d, i-vi) are shown as 
labeled in Fig. 27A-C, a (i-ii), b (iii-iv) and c (v-vi).
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For instance, 2.4 ± 0.7 nm Ag NPs in Fig. 27A-a are mostly blue and they 
will appear greenish when they are conjugated with MUNH2 groups (Fig. 27A-b) 
and even more greenish in AgMUNH2-OFLX NPs (Fig. 27A-c). Besides, the peak 
wavelengths of representative LSPR spectra of 2.4 nm Ag carriers also showed a 
red shift from Ag NPs to AgMUNH2 NPs, and to AgMUNH2-OFLX NPs (i-vi of Fig. 
27A-d). The other two sized Ag carriers have also shown a stepwise red shift in 
the peak wavelengths of representative LSPR spectra from bare Ag NPs to 
AgMUNH2NPs, and to AgMUNH2-OFLX NPs as shown in Fig. 27B and C (Fig. 
27B -13.0 nm Ag carriers, Fig. 27C- 92.6 nm Ag carriers).
Those above results demonstrated that each sized Ag NPs were 
successfully synthesized and conjugated with MUNH2 groups and OFLX 
molecules step by step, and their optical properties were also well characterized 
by UV-visible spectroscopy, DFOMS and LSPR spectroscopy.
Calculation of conjugation ratios of OFLX molecules to AgMUNH2 NPs in 
each sized AgMUNH2-OFLX NPs
Briefly, the standard UV-visible spectra curves of OFLX alone at different 
concentrations were obtained first to calculate the extinction coefficient of OFLX 
solution. Then, the concentration of conjugated OFLX molecules in each sized 
AgMUH2-OFLX NPs was calculated from the net spectra of conjugated drugs by 
subtracting the UV-visible spectra of AgMUNH2-OFLX and AgMUNH2 






CO 0 I11 •>
450 650 850
Wavelength (nm)
Fig. 27 Characterization of three sized Ag, AgMUNH2 and AgMUNH2-OFLX 
NPs by DFOMS and LSPR spectroscopy.
Representative dark-field images and LSPR spectra of 2.4 nm (A), 13.0 nm (B) 
and 92.6 nm (C) Ag carriers, respectively. Dark-field images of bare Ag NPs (a), 
AgMUNH2 NPs (b) and AgMUNH^OFLX (c) NPs and representative LSPR 
spectra (d) of single Ag, AgMUNH2, AgMUNH2-OFLX NPs (i-ii: Ag NPs, iii-iv: 
AgMUNH2 NPs, v-vi: AgMUNH2-OFLX NPs )
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ratios of OFLX molecules to AgMUNH2 NPs for each sized AgMUNH2-OFLX NPs 
(Table 4) are calculated from dividing the concentration of conjugated OFLX 
molecules by the concentration of that sized AgMUNH2 -OFLX NPs solution.
As shown in Table 4, the conjugation ratios of OFLX molecules to single 
AgMUNH2 NP in AgMUNH2-OFLX NPs are 863:1, 9435:1 and 652941:1 for the 
2.4 nm, 13.0 nm and 92.6 nm sized AgMUNFh-OFLX NPs, respectively.
Table 4 Calculation of conjugation ratios of ofloxacin (OFLX) molecules to 

















ratio of OFLX 
to AgMUNH2
2.4 50 0.337 43.152 863.0
13. 0 3.3 0.243 31.136 9435.0
92.6 0.02975 0.152 19.425 652941.8
a
Amax = 288 nm
b
e (1/uM cm), 288 nm = 0.0078
Stability study of AgMUNH2-OFLX NPs in modified LB medium
Stability studies of each sized AgMUNH2-OFLX NPs in the culture medium 
are very crucial prerequisites for further assessment of the antibacterial efficiency 
of these NPs. Preliminary studies indicated all three sized AgMUNH2-NPs are
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not stable in the LB medium (data not shown), so we modified the LB medium. 
To study the stability of NPs in the modified medium, we determined the number 
of single NPs using DFOMS as described previously [38, 39]. The concentrations 
of each sized AgMUNH2-OFLX NPs used here were 6 nM, 0.08 nM and 7 pM for 
2.4, 13.0 and 92.6 nm AgMUNH2-OFLX NPs, respectively (Note that for each 
sized NPs, the concentration used to study their stabilities in the culture medium 
here was much higher than that required for the later MIC experiments). A 
minimal of 20 images at each time point from representative locations for each 
experiment was acquired and the experiment was repeated three times. Results 
were shown in Fig. 28A-C, which represented the average number of AgMUNH2- 
OFLX NPs per image versus time in modified LB medium for 2.4 nm, 13.0 nm 
and 92.6 nm sized AgMUNH2-OFLX NPs, respectively.
Notably, for each sized AgMUNH2-OFLX NPs (2.4 nm, 13.0 nm and 92.6 
nm, respectively), the average number of NPs per image versus time remained 
unchanged over 24 h of incubation (Fig. 28A-C). This indicated that all sized 
particles were stable in the modified LB medium for at least 24 hrs at the studied 
concentrations. These positive results paved the way for further utilization of 
these silver nanoparticles conjugated antibiotics in gram-negative Pseudomonas 
aeruginosa cells in order to asses their potential antibacterial effects by 
measuring the MIC values of silver nanoparticles conjugated OFLX compared to 
their free forms in different P. aeruginosa strains containing different level of 
expression of the MexA,B-OprM pump proteins (Wide type - PAOl and MexA,B- 
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Fig. 28 Stability study of three sized AgMUNH2-OFLX NPs in modified LB 
medium for over 24 hrs by DFOMS.
Results are shown as the average number of particles per image taken from a 
high resolution color camera for each sample prepared in a micro-channel slide. 
Concentrations of three sized AgMUNH2-OFLX NPs used in this study are 6nM, 
0.8 nM and 7 pM for 2.4 nm (A), 13.0 nm (B) and 92.6 nm (C) sized AgMUNH2- 
OFLX NPs, respectively
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Besides, we also studied the stability o f those AgMUNH2-OFLX NPs in 
modified LB medium by UV-visible spectroscopy [38, 39, 97, 98], As shown in 
Fig. 29, the UV-visible spectra of each sized AgMUNH2-OFLX solution remain 
the same over 24 h of incubation. Combining the results of stability studies by 
DFOMS above and UV-visible spectroscopy, all indicated that three sized 
AgMUNH2-OFLX NPs are stable in the modified LB medium over the 24 hrs of 
time.
Cells function properly in the modified LB medium
After we verified that three sized AgMUNH2-OFLX NPs are stable in the modified 
LB medium for at least 24 hrs, our next step would be to check the efflux 
functions of different P. aeruginosa strains in the modified LB medium. We used 
the time course incorporation of fluorescent dyes (EtBr, 10 pM) to probe the 
efflux functions of different P. aeruginosa strains as previously studied [38, 99]. 
As shown in Fig. 30, for each of strains, efflux kinetics of EtBr molecules by each 
of three P. aeruginosa strains were nearly the same in both LB medium (A) and 
modified LB medium (B), with the highest accumulation of intracellular EtBr 
molecules in the pump deleted strain (AMexA,B-OprM), followed by a moderate 
accumulation of Etbr in wide type strain (PA01) and the lowest accumulation of 
EtBr in the pump overexpressed strain (NalB). This indicated that modified LB 
medium was fully capable of maintaining original efflux functions of these strains. 
Those results are quite consistent with previous studies from our and other 



















Fig. 29 Stability study of three sized AgMUNH2-OFLX NPs in modified LB 
medium by UV-visible spectroscopy.
The UV-visible spectra of each sized AgMUNH2-OFLX solution in modified LB 
medium at t Oh (a) and 124h (b) are shown as 2.4 nm AgMUNH2-OFLX (A), 13.0 
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Fig. 30 Time course incorporation of EtBr (10 pM) in different strains of 
Pseudomonas aeruginosa cultured in LB and modified LB medium.
Different P. aeruginosa strains were cultured in LB (A) and in modified LB 
medium (B), respectively, (a) Pump deleted AMexA.B-OprM strain, (b) Wide type 
PAOl strain, (c) Pump overexpressed NalB strain
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Fig. 31 Characterization of the viability of single P. aeruginosa cells using 
live/dead bac/Light viability assay.
(A) Dark field optical image and (B) green fluorescence images of WT PAOl 
cells cultured in LB medium in the cell viability assay, respectively. (C) Plots of 
percentage of viable cells (%) in LB (a) and modified LB medium (b) for each of 
three P. aeruginosa strains, respectively
PA01 delABM
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Next, we did the cell live / dead viability assay at the end of cell function 
studies to see if the number of viable or dead cells grew in these two mediums is 
approximately the same as previously studied [37, 38]. Fig. 31A-B showed the 
representative dark-field and fluorescence images of cells in this viability assay, 
more than five hundred cells from multiple images are used to calculate the 
number of viable cells for each strain in either regular or modified LB medium. 
As shown in Fig. 31C, for each of three P. aeruginosa strains, the number of 
viable cells in two types of LB mediums is nearly the same (about 98%).
Size dependent antimicrobial effects of AgMUNH2-OFLX NPs in different P. 
aeruginosa strains
To investigate the antimicrobial effects of AgMUNH2-OFLX NPs in P. 
aeruginosa cells, MICs of AgMUNH2 conjugated OFLX were determined for each 
sized NPs with the respective free forms of OFLX and corresponding AgMUNH2 
NPs as controls. At the end of the experiment, bulk images of glass tubes for 
each group of nano-carriers were taken as shown in Fig. 32-34 for PA01 and 
AMexA,B-OprM strains, respectively. Those images clearly demonstrated that
92.6 nm sized AgMUNH2 NPs conjugated OFLX molecules generated the 
highest antibacterial effects followed by 13.0 nm and 2.4 nm sized AgMUNH2 
NPs conjugated OFLX at the same concentration of conjugated OFLX molecules, 
no matter which strain was used.
Optical densities at 600 nm of samples in each glass tube were measured 
and results were plotted against the concentrations of conjugated OFLX
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molecules as shown in Fig. 34. The MIC curves showed the same trend of 
antimicrobial effects generated by different sized AgMUNH2-OFLX NPs as we 
observed from the glass tube images in Fig. 32-34, which is that larger sized 
AgMUNH2 NPs conjugated OFLX molecules generated more inhibitory effects on 
the growth of bacteria in both strains. Those results all implied the size- 
dependent inhibitory effects of AgMUNH2 NPs conjugated OFLX molecules on 
the growth of gram-negative bacteria, P. aeruginosa.
We also found that the drug deficient AgMUNH2 groups did little impact on 
the cell survivals compared to their counterparts with drug conjugated at the 
same concentrations, which implied that AgMUNH2 NPs posed little toxic or 
antimicrobial effects when Ag NPs were coated with extra MUNH2 groups on 
their surfaces, though several reports have shown the antibacterial effects of 
pure silver NPs [150, 152], In addition, our results indicated that toxic effects of 
silver NPs could be effectively circumvented when other chemical groups are 
coated on their surfaces, which is very important for future application of silver 
NPs as effective drug carriers for specifically targeting and treating diseased 
areas without harming the surrounding health cells.
Besides, we can also see that as the size of silver NPs increases, it also 
leads to higher antimicrobial effects since MIC values of conjugated OFLX in 
PA01 cells decreased from > 2.16 uM (2.4 nm AgMUNH2-OFLX NPs) to 1.08 uM 
(13.0 nm AgMUNH2-OFLX NPs), and to 0.6 nM (92.6 nm AgMUNH2-OFLX NPs ) 





(A) OFLX alone group, tubes (a-i) represent different concentrations of OFLX in 
each glass tube as 0, 0.2, 0.4, 0.6, 0.8, 1.08, 1.62, 2.16 pM, respectively. (B) 2.4 
nm AgMUNH2-OFLX NPs, the conjugated concentrations of OFLX in tubes (a-h) 
are 0.2, 0.4, 0.6, 0.8, 1.08, 1.62, 2.16 pM, respectively; tube (i) contains 2.16 pM 
of 2.4 nm AgMUNH2 control NPs. (C) 13.0 nm AgMUNH2-OFLX NPs. (D) 92.6 
nm AgMUNH2-OFLX NPs, the concentrations of OFLX in tubes (Fig. 32C-D, a-i) 
are identical to the ones in Fig. 32B, tube (i) also contained the AgMUNH2 control 
NPs of 13.0 and 92.6 nm, respectively. For all sized AgMUNH2-OFLX NPs, the 
concentration of conjugated OFLX is calculated based on the concentration of 
AgMUNH2-OFLX NPs solution and the conjugation ratio of OFLX to that sized 
AgMUNH2 NPs
Fig. 33 Images of glass tubes showing MIC study of OFLX in AMexA,B- 
OprM cells.
(A) OFLX alone group, glass tubes (a-i) represent different concentrations of 
OFLX in each tube as 0, 0.02, 0.04, 0.06, 0.08, 0.11, 0.14, 0.27 pM, respectively.
(B) 2.4 nm AgMUNH2-OFLX NPs, the conjugated concentrations of OFLX in 
tubes (a-h) are 0.02, 0.04, 0.06, 0.08, 0.11, 0.14, 0.27 pM, respectively; tube (i) 
contains 0.27 pM of 2.4 nm AgMUNH2 control NPs. (C) 13.0 nm AgMUNH2- 
OFLX NPs. (D) 92.6 nm AgMUNH2-OFLX NPs, the concentrations of OFLX in 
tubes (Fig. 33C-D, a-i) are identical to the ones in Fig. 33B, tube (i) also 
contained the AgMUNH2 control NPs of 13.0 and 92.6 nm, respectively. The 
concentrations of conjugated OFLX for all sized AgMUNH2-OFLX NPs are 
calculated using the same approaches as described in Fig. 32
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Concentration of Conjugated OFLX (pM)
Fig. 34 MICs of OFLX in PAOl and AMexA, B-OprM cells.
Optical density values (O D e o o n m )  of each sample in wt PA01 (A) and AMexA, B-
OprM (B) cells are plotted against the concentrations of conjugated OFLX (pM) at
the end of MIC experiment; (a) 2.4 nm AgMUNH2, (b) 13.0 nm AgMUNH2) (c)
92.6 nm AgMUNH2, (d) 2.4 nm AgMUNH2-OFLX, (e) OFLX alone, (f) 13.0 nm
AgMUNH2-OFLX and (g) 92.6 nm AgMUNH2-OFLX. Error bars represent the
standard deviations from three repeated experiments for each sample
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MICs of conjugated OFLX in AgMUNHz- 
OFLX NPs (pM) Reference
PAOl AMexA,B-OprM
2.4 nm >2.16 >0.27
13.0 nm 1.08 0.14
92.6 nm 0.6 0.06
OFLX alone 2.16 0.27 [13]
The results from MIC studies in the AMexA,B-OprM strain (Table 5, Fig. 
34B) showed the similar trend as seen in wide type PA01 strain. First, drug free 
AgMUNH2 NPs of three sizes had little or no antibacterial effects. Secondly, drug 
conjugated AgMUNH2-OFLX NPs exhibited antibacterial effects as a function of 
size of AgMUNH2 NPs.
For example, as the size of AgMUNH2 NPs increased from 2.4 nm to 13. 0 
nm, and to 92.6 nm, the MICs of OFLX for these different sized AgMUNH^OFLX 
NPs in AMexA,B-OprM strain were decreased from > 0.27 pM to 0.14 pM and to 
0.06 pM, respectively. From these results, we found that 2.4 nm AgMUNH2- 
OFLX NPs are probably the most biocompatible NPs since their MIC values are 
close to those in the OFLX drug alone group for both strains while the other two 
sized AgMUNH2-OFLX (13.0 nm and 92.6 nm) can generate more antimicrobial 
effects when they are conjugated with drugs.
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Those interesting results not only confirm the existence of enhanced 
antimicrobial effects of the drug (OFLX) conjugated silver NPs but also suggest 
those effects are largely dependent on the size of NP carriers. As the size of 
particles increases, their surface areas also tremendously enlarge which made it 
possible for conjugating larger number of drug molecules to single particle. 
These particles with higher conjugation ratios of drug molecules will offer greater 
advantages over those with lower conjugation ratios for targeting and binding 
with specific biological molecules and conferring the potent effects of loaded 
drugs. These phenomena have been observed in many previous studies [33, 35, 
40, 147, 149], For example, Burygin et al. found enhanced antibacterial activity 
of antibiotics mixed with gold NPs [40] and Bhattacharya et al. found that gold 
NPs conjugated drugs showed greater bactericidal activity and reduced MIC 
compared to their respective free forms [35]. Though these studies observed the 
enhanced antimicrobial effects from drug or antibiotics conjugated NPs, it 
remains unanswered about the exact mechanisms governing these enhanced 
antibacterial effects.
SUMMARY
In this study, we have successfully synthesized three sized silver NPs (2.4 
± 0.7, 13.0 ±3.1 and 92.6 ± 4.4 nm) and conjugated them with antibiotic (OFLX). 
We also modified the regular LB medium and found that different P. aeruginosa 
strains cultured in modified LB medium can still maintain their original efflux 
functions as compared with those cultured in regular LB medium without
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significant changes in terms of cell function and cell viability. Next, we found 
size-dependent antimicrobial effects generated by these different sized 
AgMUNH2-OFLX NPs in one of gram-negative, clinically important bacteria, P. 
aeruginosa, with larger sized AgMUNH2-OFLX (92.6 nm) NPS showing the 
highest bactericidal effects, followed by a middle sized AgMUNH2-OFLX (13.0 
nm) and finally the smallest sized AgMUNH2-OFLX (2.4 nm) which result is quite 
similar to that of the antibiotic alone group. These results indicate that 2.4 nm 
silver NPs are probably the most biocompatible silver NPs for sensing and 
imaging bio-molecules while the other bigger sized silver NPs, due to their higher 
efficiency of antibacterial effects, can be used as efficient drug carriers in the 
treatment of many diseases.
In summary, our studies clearly showed the existence of size-dependent 
antibacterial effects of AgMUNH2 NPs conjugated OFLX and these important 
findings will aid in the application of nano-materials conjugated with different 
types of drugs for cancer therapy in the future.
METHODS
Reagents and supplies
Silver perchlorate monohydrate (99%, Alfa Aesar), sodium citrate 
dihydrate (99%, Sigma), 2-mercaptoethanol (99%, Sigma), 11-amino-1- 
undecanethiol hydrochloride (MUNH2, 99%, Sigma) and sodium borohydride 
(98%, Sigma) were used, as received, for synthesis of Ag NPs. Live/dead 
bacLight viability and counting assay were purchased from Invitrogen; all other
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reagents like LB powder, ofloxacin (OFLX), were purchased from Sigma- 
Aldrich. 1-Ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride (EDC, 
99%) and N-hydroxysulfosuccinimide (s-NHS, 98.5%) were from Pierce.
Synthesis and characterization of different sized silver (Ag) nanoparticles
Three different sized Ag NPs (2.4 ± 0.7 nm, 13.0 ±3.1 nm and 92.6 ± 4.4 
nm) were synthesized and purified as described previously [38, 42, 43]. Briefly, 
for the synthesis of 2.4 ± 0.7 nm Ag NPs, 0.11 mM of AgN0 3 , 1.91 mM of sodium 
citrate, 0.052 mM of PVP, and 25.0 mM of H20 2 in nanopure water (42.3 mL) 
were prepared freshly, mixed and stirred constantly. Then, we added NaBH4 
(150 pL, 100 mM) into the mixture, the solution color turned to light yellow. After 
stirring for another 3 h, the solution was then filtered using 0.2 pm membrane 
filters (Whatman). For the synthesis of 13.0 ± 3.1 nm Ag NPs, AgCI04 (2.5 mL, 
10 mM, ice-cold) was added into the stirring mixture (247.5 mL) of ice-cold 
sodium citrate (3 mM) and NaBH4 (10 mM), and the mixture was stirred at room 
temperature for additional 4 h. The solution was then filtered using 0.22 pm filters 
(Whatman) and washed twice with nanopure Dl water using ultracentrifugation at 
15000 RCF (relative centrifugal force), to prepare stable and purified Ag NPs. For 
the synthesis of 92.6 ± 4.4 nm Ag NPs, we added sodium citrate (34 mM, 10mL) 
into a refluxing (100 °C) stirring aqueous solution of AgN03 (3.98 mM, 500 mL) 
and stirred it for 35 min. Then, we stopped stirring and heating the mixture and 
allowed it to cool to room temperature. We added additional sodium citrate (2.5 
mM) to further stabilize the NPs in solution. The solution was then filtered via
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0.22 pm filters and washed three times using nanopure Dl water via 
centrifugation. The purified Ag NPs were dispersed in the PBS buffer (0.5 mM 
phosphate buffer, 1,5 mM NaCI, pH=7.0). The sizes of single NPs were 
determined using high-resolution transmission electron microscopy (HRTEM) 
(FEI Tecnai G2 F30 FEG). The concentrations of NPs were measured and 
calculated, as described previously [38, 42, 43]. Plasmonic absorption and 
scattering properties of bulk NPs were characterized using UV-visible 
spectrometry (Hitachi).
Conjugation of ofloxacin (OFLX) to AgMUNH2 NPs and calculation of 
conjugation ratios of drug molecules to AgMUNH2 NPs
1 mL 100 mM MUNH2 in ethanol was added to 100 mL freshly prepared 
Ag NPs of three different sizes (2.4 ± 0.7, 13.0 ± 3.1 and 92.6 ± 4.4 nm), 
respectively. The mixtures were stirred for 24 h to attach MUNH2 onto the surface 
of NPs via their interaction of thiol groups with NPs. The AgMUNH2 NPs were 
washed twice by nanopure water to remove excess MUNH2 using centrifugation 
(Beckman Optima L90k), 30k rpm (60 min) for 2.4 ± 0.7 nm AgMUNH2, 12k rpm 
(90 min) for 13.0 ± 3.1 nm AgMUNH2 and 2.5k rpm (20 min) for 92.6 ± 4.4 nm 
AgMUNH2 at 4 °C. The AgMUNH2 NPs were immediately characterized using 
UV-visible spectroscopy, dark-field optical microscopy and spectroscopy 
(DFOMS), and dynamic light scattering (DLS). The amine groups of AgMUNH2 
NPs were conjugated to the carboxyl group of OFLX via peptide bonds using 
EDO and s-NHS as mediators. OFLX was first dissolved in 0.5 M HCI and then
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diluted to 10 mM by MES buffer (pH 5.0, 50mM). EDC (30 pmol) and s-NHS (150 
pmol) were added to OFLX (3 mL, 50 mM), forming OFLX-s-NHS esters. After 
stirring at room temperature for 40 min, the reaction was stopped by adding 10 pi 
2-mercaptoethanol. Then, 1 mL OFLX-s-NHS esters was added to 100 mL Ag 
MUNH2 NPs of three different sizes, respectively. The solutions were mixed 
using a rotary shaker at room temperature for 3 h. The final products (AgMUNH2- 
OFLX NPs of three different sizes) were washed using centrifugation, 30k rpm 
(60 min) for 2.4 nm AgMUNH2-OFLX, 12k rpm (90 min) for 13.0 nm Ag MUNH2- 
OFLX and 2.5k rpm (20 min) for 92.6 nm Ag MUNH2-OFLX. The purified 
AgMUNH2-OFLX NPs were resuspended in 50 mM PBS (pH 7.0) and stored at 4 
°C for the future use. The sizes and optical properties of AgMUNH2-OFLX NPs 
were characterized using DLS, UV-visible spectra and DFOMS.
Conjugation ratios of drug (OFLX) to each of three sized AgMUNH2 NPs 
were calculated as described below. First, a standard curve was generated by 
measuring the absorbance value (A) at peak wavelength (A = 288 nm) from the 
absorption UV-visible spectra for different concentrations of OFLX alone 
solutions to calculate the absorption coefficient (e). Next, to get the absorbance 
scale for each sized AgMUNH^OFLX NPs, we divided the absorbance value at A 
= 288 nm by corresponding height (mm) from the UV-visible spectra of each 
sized AgMUNH2-OFLX solution at stock concentration (50 nM for 2.4 nm, 3.3 nM 
for 13.0 nm and 0.02975 nM for 92.6 nm AgMUNH2-OFLX NPs, respectively). 
After that, we calculated the net height (cm) of absorbance at 288 nm 
corresponding to the part of conjugated OFLX by subtracting the height a=288 nm
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from spectra of AgMUNfVOFLX solution to the height a=288 nm from spectra of 
AgMUNH2 solution alone. Then, we got the concentrations of conjugated OFLX 
for each sized AgMUNH2-OFLX NPs from each value of absorbance scale timing 
net height of absorbance for conjugated OFLX part. Finally the conjugation ratio 
for each sized AgMUNH2-OFLX NPs is calculated by dividing the concentration 
of conjugated OFLX to its stock concentration of AgMUNH2-OFLX solution, 
respectively.
Stability study of AgMUNH2-OFLX NPs in modified LB medium
Studies of stability of AgMUNH2-OFLX NPs in modified LB medium were 
done by monitoring the UV-visible spectra changes and directly countering the 
average, number of NPs from 10 images by DFOMS on a slide prepared from the 
solution containing each sized AgMUNH2-OFLX NPs in modified LB medium at 
four different time points over 24 h of incubation. The concentration used for 
each sized AgMUNH2-OFLX NPs in those stability studies is much higher than 
required for the later MIC experiment according to previous MIC studies of OFLX 
alone in different P. aeruginosa strains [13]. All experiments have been repeated 
at least three times.
Cell function and viability assay in modified LB medium
To investigate if the cell functions have changed or not in the modified LB 
medium, we studied the efflux functions of different P. aeruginosa strains (wide 
type PA01, NalB with efflux pump overexpressed and AMexA,B-OprM with
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MexA,B-OprM pump deleted). A single colony from freshly streaked plates for 
each of three strains were inoculated into 15 mL regular and modified LB 
medium and cultured with vigorous shaking (200 rpm, 37 °C). Samples were 
taken out for measuring the optical density (ODeoo nm) every 30 min up to 12 hrs 
of culture. Time course incorporation of ethidium bromide (EtBr, 10 pM) in the 
above P. aeruginosa strains were monitored over a two-hour period on a 
fluorescence spectrometer. The excitation and emission wavelength were set at 
465 and 600 nm with a slit of 10 and 10 nm width, respectively.
Cell viability assay were done according to the manufacture’s instruction 
(Bac Live / Dead viability assay from Invitrogen). The percentage of live and 
dead cells were calculated from multiple images of both Dark Field and the 
corresponding Green / Red fluorescence images for over 500 cells in total for 
each strain used.
Study of MIC of OFLX in different P. aeruginosa strains
To investigate the antibacterial effects of silver NPs with or without drug 
molecule (OFLX) conjugated, we directly measured the MICs of OFLX in different 
P. aeruginosa strains for those different sized AgMUNH2-OFLX NPs. For either 
PA01 or AMexA,B-OprM strain used here, about 104 cells from a pre-culture 
solution were inoculated into the modified LB medium containing a set of different 
concentrations of OFLX (concentrations of corresponding OFLX for three sized 
AgMUNH2-OFLX NPs are calculated based on their conjugation ratios, 
respectively; AgMUNH2 NPs of each size and OFLX alone were used as
controls). Cells are cultured in a 15 mL test tube (4 mL volume in total) with 
vigorous shaking (200 rpm, 37 °C) for about 18 hrs, samples were taken out at 
different time points (T 6 h, T 12h and T 18h) for measuring the values of optical 
density ( O D 6oo nm)- Results of MIC studies were plotted with Optical density 
( O D 6oo nm) values versus the concentrations of conjugated OFLX molecules 
calculated from the conjugation ratio of each sized NPs and the concentration of 




In summary, this dissertation presents structural and functional studies of 
multidrug membrane transporters using molecular biology approaches, structural 
modeling, cutting-edge single NP plasmonic spectroscopy and dark-field optical 
microscopy and spectroscopy. Two representative MDR transporters, ABC (ATP- 
binding cassette, BmrA) and RND (resistance-nodulation-cell division, MexA.B- 
OprM) in gram-positive and gram-negative bacteria (B. subtilis and P. 
aeruginosa), are studied in real-time at single cell resolution.
In Chapter II, we fused EGFP with the N-terminus or C-terminus of BmrA 
to construct BmrA-EGFP fusion proteins and characterized their efflux functions 
in four strains of B. subtilis cells (Nt-BmrA-EGFP, Ct-BmrA-EGFP, BmrA, and 
ABmrA, B. subtilis) using fluorescence microscopy and spectroscopy. Fusion of 
ABC membrane transporters with EGFP offers the opportunity to visualize 
membrane transporters and study their interactions with substrates that lead to 
their translocations. Note that the fusion of ABC transporters with EGFP (BmrA- 
EGFP) may alter their efflux functions. Therefore, it is very crucial that we first 
characterize heir efflux functions prior to using them to probe molecular 
mechanisms of membrane transporters. The results show that BmrA-EGFP 
fusion proteins exhibit the similar efflux kinetics of BmrA and retain the efflux 
functions of BmrA. Modeled structures of the fusion proteins show a highly
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flexible linker region connecting EGFP with BmrA, suggesting a minimal 
obstruction of EGFP to the BmrA.
In Chapter III, we studied the size-dependent efflux functions of BmrA- 
EGFP and BmrA using single plasmonic nanoparticle imaging probes and 
spectroscopy, and found size-dependent efflux kinetics of BmrA transporter. 
These two new stains of BmrA-EGFP offer the possibility for one to visualize 
BmrA transporter and study efflux function and mechanisms of BmrA.
In Chapter IV, using the similar approaches, we fused EGFP with MexB 
(subunit of MexA,B-OprM transporter) and characterized efflux functions of fusion 
protein (MexA-EGFP-MexB-OprM) using fluorescence spectroscopy. The results 
show that the EGFP fusion strain only partially retains the original efflux functions 
of MexA,B-OprM transporter. Structural analysis of fusion protein suggests 
possible steric hindrance of EGFP towards the conformational arrangements of 
MexA,B-OprM tripartite proteins, which led to the steric effect upon their efflux 
functions.
In Chapter V, we further functionalized Ag NPs with the antibiotic 
(ofloxacin), which is a representative substrate of MexA,B-OprM transporter in P. 
aeruginosa. We studied the antibacterial effects of ofloxacin alone (absence of 
the NPs), and various sized Ag NPs conjugated with ofloxacin. We found that the 
larger sized Ag NPs conjugated ofloxacin showed the lower MICs and higher 
inhibitory potency towards the bacterial growth in P. aeruginosa.
In summary, we have studied the structures and functions of two different 
types of MDR efflux pumps (ABC and RND) in both gram negative and gram
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positive bacteria using fluorescence microscopy and spectroscopy, and single 
plasmonic microscopy and spectroscopy. The results offer new insights into the 
structural and functional studies of multidrug membrane transporters (efflux 
pumps), and have demonstrated the power of integrating new nanotechnology 
approaches with molecular biology techniques for better understanding of MDR.
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